Company Stories D-E

Dabble (St Louis, MO)

Dabble  (St Louis, MO; no SBIR) , a California-based startup brought to St. Louis last year after it won a $50,000 Arch Grant, has moved to Chicago and raised $1 million from a group of [Chicago] investors ... [CEO] said he’d tried for months to raise money in St. Louis   [Brian Feldt, St. Louis Business Journal, Dec 9, 15]

Dairyvative Technologies (Markesan, WI)

Dairyvative Technologies LLC (Markesan, WI; no SBIR, founded 2012, seven employees) with a technology for concentrating milk to give it a longer shelf life and make it lactose free, has raised $2.5 million from four investors, according to [SEC] filing [Milwaukee Journal Senitnal, Nov 30, 15] a super-concentrate, only requires one truck where before we needed seven.  We can now ship product across the country to where it is needed at a fraction of the price and with huge sustainability benefits.  [company website]

Daktari Diagnostics (Arlington, MA)

biotech startup Daktari Diagnostics (Cambridge, MA; no SBIR) has raised $5 million of a planned $10 million financing round made up of equity placement and debt, federal documents show. ... working on a low-cost HIV point-of-care test that can perform critical CD4 white blood cell counts, to be used to monitor the effectiveness of AIDS treatments in developing countries.  [Rodney Brown, Mass High Tech, Dec 28, 11]

Daktari Diagnostics (Cambridge, MA; no SBIR)  biotech developing blood-based diagnostic tools for the developing world, has reported a $1.25 million debt funding  ... founded in 2008, reported that it has sold $1,178,530 so far in the offering. The company had raised at least $5 million in total during three previous equity rounds  [James Connolly, Mass HIgh Tech, Aug 17, 11]

Daktari Diagnostics (Arlington, MA; no SBIR) raised $2.5M of a planned $2.9M equity financing. [Mass High Tech, Aug 27, 09]

Dance Biopharm (Brisbane, CA)

Drug maker Dance Biopharm (Brisbane, CA; no SBIR) called off its [IPO], amid investors' concern over potential fallout for U.S. markets from signs of weakness in the global economy. [Jason McCormick, Silicon Valley Business Journal, Oct 17, 14]

Dara BioSciences (Raleigh, NC)

In its attempt to raise $11.3 million Dara Biosciences (Raleigh, NC; no SBIR) shifted strategy again and now plans to sell preferred shares instead of common stock. ...   to license other products to add to its portfolio of drugs it can market.  [Jason deBruyn, Triangle Business Journal,  May 21, 14]  

specialty pharmaceutical company Dara Biosciences (Raleigh, NC; no SBIR) filed notice to sell additional shares, with a proposed maximum sale of $32.5 million. ....  Dara has some specialty drugs on the market, specifically Soltamox to treat breast cancer, and is developing a new treatment targeted for cancer patients.  [Jason deBruyn, Triangle Business Journal, Apr 21, 14]

Dara BioSciences (Raleigh, NC; no SBIR) is seeking to raise as much as $32.5 million through a sale of stock and warrants.  ...  to fund “commercial activities related to our product portfolio” and other uses.  .... has two products on the market: Soltamox, an oral liquid formulation used in the treatment and prevention of breast cancer, and Bionect, a topical treatment for skin irritation and burns caused by radiation. Dara also has exclusive U.S. commercial rights to market and sell Gelclair for the treatment of oral mucositis, or swelling and bleeding of the mouth and gums. [David Bracken, Raleigh News & Observer, Apr 21, 14]

Dara Biosciences (Raleigh, NC; no SBIR) sold $2.5M in converrtible stiock and warrants to further finance the commercialization of its approved cancer support products.  [Lauren Ohnesorge, Triangle Business Journal, Dec 31, 12]

Early drug safety results for Dara BioSciences' (Raleigh, NC; no SBIR) experimental diabetes medicine boosted the stock of the small drug development company about 12%. ... Dara's strategy is to license drugs that are discovered by others, develop them through the second phase of human tests and then sell the marketing rights. The company employs 10.   [Raleigh News & Observer, Jul 11, 08]

Daré Bioscience Operations

DARE Bioscience up 10% [Sep 5, 17] Cerulean Pharma and Daré Bioscience Operations, (formerly Daré Bioscience, Inc.) announced the closing of the transactions contemplated by the stock purchase agreement entered into by the companies on March 19, 2017. As a result of these transactions, (i) the former holders of Daré equity securities now hold approximately 51% of Cerulean capital stock (calculated based on the stock purchase agreement), (ii) Daré Bioscience Operations, Inc. has become a wholly-owned subsidiary of Cerulean, (iii) Cerulean is changing its name to "Daré Bioscience, Inc.," effective as of Thursday, July 20, 2017, and (iv) a one-for-ten reverse stock split of the combined company's common stock will be effected on Thursday, July 20, 2017.   [company press release, Sep 5, 17]

Dark Wolf Solutions (San Diego, CA)

US Navy awarded a $100,000,000 indefinite-delivery/indefinite-quantity multiple award contract for the development and integration of new software solutions. Companies are Dark Wolf Solutions (San Diego, CA; $2.9M SBIR); Geo4S Technologies (Catonsville, MD; $750K SBIR); ISPA Technology (Lithia, FLlorida; no SBIR); Moebius Solutions (San Diego, CA; one SBIR); Objective Function Systems (Canoga Park, CA; no SBIR); ODME Solutions (Del Mar, CA; no SBIR); Opal Soft (Sunnyvale, CA; no SBIR); Raft (Reston, VA; SBIR); TapHere! Technology (Manassas, VA; no SBIR); TDI Technologies (Coronado, CA; $1.3M SBIR); and The Marlin Alliance (San Diego, CA; no SBIR). [Naomi Cooper, govconwire, Jul 28, 2023]

Dart Therapeutics (Great Barington, MA)

Dart Therapeutics (Great Barington, MA; no SBIR), a company the Wall Street Journal profiled in its health blog this week as a “do-it-yourself drug development” company focused on developing treatment for Duchenne muscular dystrophy and funded by patient organizations....  the DIY company model that Dart has adopted has led to the formation of a new company, Halo Therapeutics  (no SBIR), after Dart bought the drug halofuginone as a potential treatment for DMD. And the model could potentially serve other rare disease drug programs.  [Michelle Lang, Mass High Tech, Dec 30, 11]

DaStrong (Buffalo,NY)

DaStrong (Buffalo, NY;  SBIR) is in the process of closing a $300,000 angel investment round from venture capitalists in China ...  has developed a product that cools electronic devices without the use of fans. The product uses electromagnetic force and is significantly less expensive, more reliable and longer-lasting than competitors, company leaders say. ...  first publicly acknowledged private capital raise from a winner of the 43North business competition ... founded by Hayden Ren and Oscar Xu when they were attending Rice University    [Dan Miner, Buffalo Business First, Aug 25, 15]  43North gives out $5 million in cash prizes each year [as] is part of New York Governor Cuomo’s Buffalo Billion initiative [43North website]

Datafiniti (Houston, TX)

Datafiniti (Houston, TX; no SBIR) is moving to Austin after having difficulty recruiting technology workers in Houston. [Christopher Calnan, Austin Business Journal, May 10, 13]

DataRobot (Boston,MA)

artificial intelligence company (Boston, MA; no SBIR) Leader in Automated Machine Learning,announced the first close in its Series C financing. ... an additional $54 million, bringing total funding to $111 million. ... “The number of AI and machine learning (ML) solutions being generated by all the data scientists in the the world is not even making a dent in the massive demand for these solutions, and this deficit is growing rapidly as executives across the globe–in all verticals–realize that an AI-driven organization is now a necessity.   It is now obvious that the only way to meet this demand is to automate the development of AI and ML solutions by teaching machines to do most of the work. This is exactly what we’ve been doing for the last 4.5 years.[company press release, Mar 23, 17]  Software is not usually a subect for this blog because it is usually only a business risk, not a techncal risk.  Software people can almost always do what they propose.  AI, though, is a risk-laden software where "correct" coding and logic are necessary but not usually also a sufficient criterion for success. But the global surplus of capital is now more willing to accept such risk in decent amounts. 

Dato (formerly GraphLab) Fremont, WA)

machine learning company GraphLab (Fremont, WA; no SBIR, founded 2013, 27 employees) announced an $18.5 million funding round led by Paul Allen's Vulcan Capital. ...  also renaming the company "Dato."   The series B funding brings the company's total funding to date up to $25.25 million   [Rachel Lerman, Puget Sound Business Journal, Jan 8, 15]

Datuit (Roseville, MN)

LifeScience Alley, the regional trade association that represents life science and health technology companies, announced that 10 organizations will be exhibiting cutting-edge products as part of the association’s New Technology Showcase at the 2013 LifeScience Alley Conference, Nov. 20 at the Minneapolis Convention Center.   Featured will be:  (Rochester, MN;  no SBIR), developing a cancer-selective virus particularly suited to destroy relapsed or metastatic cancer cells; Omnis PharmaRebiotix (Roseville, MN; no SBIR), which will present something called Microbiota Restoration Therapy, which delivers live, human-derived microbes to patients’ intestinal tracts to restore balance and treat certain diseases; and (Naperville, IL; no SBIR) will demonstrate its remote patient monitoring and predictive analytics system, which converts patient vital signs into information to aid in care.    VGBioCogCubed (Minneapolis, MN;  no SBIR) will exhibit an approach to diagnosing and treating cognitive health by analyzing game play data; Datuit (Roseville, MN; no SBIR) will display a platform allowing patients, family and clinicians to confidentially share medical information; Imanis Life Sciences   (Rochester, MN; no SBIR) will show a gene-based platform for promoting non-invasive, long-term imaging technologies in living beings; Mednology Solutions (Excelsior, MN;  no SBIR) will exhibit a system designed to improve efficiency in the management of medical emergencies; NanoVault Medical (St. Paul, MN; no SBIR) will show a cellular and biotherapeutic delivery technology to treat autoimmune diseases. ReMind Technologies of Houston, Tex., will exhibit a smartphone-based medication dispensing device and Skyline Medical, Inc. of Eagan will show an automated surgical fluid disposal device with unlimited capacity and real-time fluid volume data. For more information.  [James Walsh, Minneapolis Star Tribune, Sep 25]

Data Physics (San Jose, CA)

Battery Ventures has bought a controlling stake in -based Data Physics (San Jose, CA;  no SBIR)  ... Financial terms of the deal were not disclosed.  Data Physics designs and manufactures test and measurement tools for noise and vibration analysis and sells into sectors that range from aerospace to electronics.  ...  founded in 1984 by former Hewlett-Packard Co. employees Dave Snyder and Sri Welaratna, who will remain involved with the company. [Sarah Drake, Silicon Valley Business Journal, Feb 19, 14]

Daxor Oak Ridge, TN)

Daxor (Oak Ridge, TN; $700K SBIR) up 38% [Jun 4, 21]

Daxor down 16% [Mar 3, 20]

Daxor (Oak Ridge, TN; one SBIR) up 66% [Mar 2, 20] announces active engagement with both hospitals and government agencies in the military and civilian sectors regarding the use of its technology to help guide fluid management of critically ill patients with COVID-19. [company press release, Mar 2, 20]

daydream.io (Troy, NY)

The two [founders of daydream.io (Troy, NY; founded 2015)] met in the 1990s as employees of the Silicon Alley startup Pseudo.com that meshed social with video. Bush's connection to RPI led them to build daydream.io in Troy. ...  [co-founder Dennis] Adamo worked in marketing and business development for LG and Yahoo in Russia. [co-founder V Owen Bush] was a producer for the MTV show Amp and developed a show for the Hayden Planetarium. He came to Troy in 2003 to work at the Rensselaer Polytechnic Institute where he was part of The Molecularium Project, a planetarium show and 3D IMAX movie about atoms. ... Using Google Cardboard, daydream.io will be able to sell its device for the price of a selfie stick, about $20.  It's an industry that Forbes estimates will be worth $4 billion by 2018.   [Chelsea Diana, Albany Business Review, Sep 18, 15]

Daylight Solutions (San Diego, CA)

Leonardo (Italy)  has signed a definitive agreement to purchase Daylight Solutions (San Diego, CA; $1.8M SBIR founded 2005, 110 workers) a leading developer and supplier of quantum cascade laser products and technology. ... Daylight Solutions is expected  to grow significantly in the coming years, thanks to the rollout of new U.S. military aircraft survivability systems, where Daylight Solutions has secured significant roles.   [Leonardo press release, Mar 7, 17]

Day One Pharmaceuticals (Menlo Park, CA)

Biotech Day One Pharmaceuticals (Menlo Park, CA; no SBIR) debuts with $60M to change cancer care—starting with children. The drug has been tested in more than 250 patients, adults and children, and it’s in an investigator-sponsored trial testing it in children with relapsed gliomas. [Amirah Al Idrus, Fierce Biotech, May 21, 20]

DayStar   (Halfmoon NY)

Daystar got its share price back above a buck with a 1 for seven reverse split.

DayStar  up 20% [Jul 28, 10]

DayStar down 14% [Jul 26, 10]

DayStar Technologies up 96% [Jul 22, 10] announced it is pursuing a strategy for offshore manufacturing of its CIGS solar modules.  [Tech Trader Daily, Jul 22, 10] After $1M SBIR, economics takes over any nationalistic idea of American manufacturing.

DayStar Technologies has backed out of a deal to purchase a Canadian solar photovoltaic company.... said it will not buy EPOD Solar, based in Kelowna, British Columbia. DayStar in September said it planned to pay $300 million in preferred stock for EPOD [The Business Review (Albany), Oct 20, 09]

For all of 2008, DayStar reported a net loss of $26M [compared] to a net loss of $36M in 2007. [The Business Review (Albany), Mar 17, 09]

DayStar Technologies reported a deeper net loss for the third quarter than it had a year ago. .... a net loss of $6.7 million,   [Business Review (Albany), Nov 14, 08]

DayStar down 14% broke the buck. [Nov 21, 08] Sic transit gloria energii.

DayStar up 11% [Oct 20, 08]

DayStar up 19% [Oct 13, 08]

Daystar up 10% [Aug 28, 08]

DayStar Technologies up 11%  [May 13, 08]

DayStar up 12%  [May 8, 08]

DayStar down 15% [Mar 7, 08]

DayStar up 11% [Feb 11, 08]

DayStar down 10% [Jan 23, 08]

DayStar down 11% [Jan 17, 08]

DayStar up 25%. [Dec 31, 07]

DayStar up 24% [Dec 26, 07]

DayStar down 15% [Nov 12, 07] on decline of solar stocks with oil prices.

DayStar up 11%  [Nov 6, 07]

DayStar Technologies priced its public offering for $64M  to repay in full $9.2M in debt and to engineer and manufacture a deposition tool. [AP, Oct 26, 07]

DayStar down 13% [Oct 24, 07]

Day Star up 10%[Oct 19, 07]

DayStar up 15% [Oct 15, 07]

DayStar up 12% [Sep 26, 07]

DayStar Technologies that a former research manager stole trade secrets in that right after being notified of his intended layoff as the company moved to California, the employee began sending "the first of over 1,000 e-mails to his personal e-mail accounts," which had sensitive company information, including confidential memos, summaries of experiments, research findings, copies of patent applications and studies. [Larry Rulison, Albany Times-Union, Sep 22]

DayStar up 28% [Sep 19,07]

DayStar said it will start planning in 20008 for a 100-megawatt solar-cell factory to be built in 2009. [Albany Times Union, Aug 12,07]

DayStar Technologies up 10%.  [Aug 8, 07]

DayStar up 11% on announcement of new issue of shares. [Aug 6, 07]

DayStar down 10% [Jul 27, 07]

DayStar up 14% [Jul 13, 07]

DayStar up 31% [Jun 25, 07]

DayStar Technologies is scrambling for $25M in equity financing by the end of July as it abandons New York's $11M incentive to return to California and build a manufacturing site for thin-film solar cells. [Albany Times-Union, Jun 22] Gearing up for serious business and going public are not recreational diversions from doing SBIR for the government money.  It takes serious money, serious adults, and serious attitudes.

DayStar shot up 24% [May 18, 07]

DayStar down 10% [May 15, 07] as it will move its headquarters back to [Santa Clara] California and cut 20 jobs locally [in Halfmoon NY] in a bid to survive. [Eric Anderson, Albany Times Union, May 16] New York State wants its incentive money back.

DayStar shot up 24% [Mar 14, 07]

DayStar Tech down 14% [Mar 5, 07]

DayStar up another 20%  [Feb 26, 07]

DayStar Technologies up 11% [Feb 23, 07].

A local VC put up 10% of a $5M VC investment in DayStar by New York investors. Michael Dura is also on the board of Evident Tech, a Troy NY nanofirm. [Albany Times-Union, Jan 26, 07]

DayStar up another 16% [Jan 18, 07]. It announced a financial restructuring of a $15 M investment by a hedge fund and agreeing to sell $5 M in additional stock. [Larry Rulison, Albany Times-Union, Jan 20]

DayStar up 25% [Jan 17, 07]

Daystar exploded, up 52% [Jan 11, 07] without company news. The local paper reports only speculation, .Are there brighter days ahead for DayStar?

Rough Start.  DayStar dropped 18% atop a 14% drop on the year's first trading day. [Jan 07]

A potential financing deal between DayStar Technologies and a New York investment firm appears to have fallen through. [Albany Times-Union, Dec 8] No $15M and a new CEO.

DayStar jumped 13% on news that its solar cell production is exceeding expectations.  DayStar had one Phase 2 SBIR for $1M from MDA four years before it went public in 2004. From three employees for the SBIR, it has expanded to 50 employees although revenue is still tiny as it builds  production capacity and loses a few million a year from private sector capital and $11M state handout to move to Halfmoon NY from California. Halfmoon is on the edge of the Capital District which has seen several other successful small high-tech firms some of whom benefitted from a relationship with Rensselaer Polytechnic. I'll confidently guess that the competition for SBIR in MDA induced DayStar into getting third party financing for commercialization as a condition of most of the Phase II million since there had been many life-style companies wanting to dabble risk-free in the photovoltaic chemistry that DayStar exploits. [Sep 06]

DayStar aims to manufacture a [CIGS solar] cell that is competitive on performance, cost and durability. [Albany Times Union, Aug 5]  ... CIGS technology has an extensive 20+ year history and became commercially viable in part due to the leadership of [founder] Dr. Tuttle and his associates during his 11- year tenure at the DOE’s National Renewable Energy Laboratory.  One DOD (MDA at the end of its decade of SBIR innovation) Phase 2 SBIR for $1M in 2000, three years after founding and with only three employees, in a technology that had been advancing incrementally for years.  Now it has 79 employees as a public company since 2004, having accepted an $11.2M relocation package from NY State and moved the Company’s operations from California. MDA would do well to advertise its ROI for the early investment, but MDA is no longer inclined to look for, or even at, economic ROI.

DayZero Diagnostics(Boston, MA)

Day Zero Diagnostics (Boston, MA; $200K SBIR, founded 2016) an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced it was awarded up to $6.2 million in non-dilutive funding [to]support the development of Day Zero’s diagnostic system that is intended to help physicians quickly and accurately diagnose and treat life-threatening bacterial infections. [company press release, May 11, 20]

DayZero Diagnostics (Boston, MA; no SBIR,  founded 2016) an infectious disease diagnostic company using genome sequencing and machine learning to enable rapid and precise treatment in an era of growing antibiotic resistance, announced the completion of a $8.6M Series A round. .... developing a sequencing-based rapid diagnostic that identifies, within hours, both the species and the antibiotic resistance profile of a bacterial pathogen. [company press release, Jan 23 19] prior funding $12M [crunchbase.com]

DBS Energy

Grab Your Politician for Plus-Up. Smaller and more transparent earmarks of federal funds for favored domestic projects are returning after a one-year moratorium on the controversial practice. ... a bit less than 1% of total R&D appropriations (3% for DOD) ... The Senate Top 10, are mostly smaller states with senators in key committee chairmanships—Mississippi, New Mexico and Tennessee are at the top. ... search AAAS's new database of 2008 earmarks [AAAS Newsletter, Sep 07] But for small business, even 1% is a big honey pot. In the list (August version): Electro Energy  (CT; SBIR), Ocean Power Technologies (OR, SBIR in NJ),  DBS Energy CT, Eikos (MA; $8M+ SBIR), Cellular Bioengineering HI, Cerematec  (UT; SBIR), Ramgen WA, Advanced Radar Technologies WY, Compact Membrane Systems (DE; $20M SBIR), SD Catalyst Group SD.  Your story is that high-tech small business will create jobs, and they don't know whether your claim is valid or just wishful thinking. Like the federal mission agencies who then have to award and supervise the contract, they don't seem much to care.

DecImmune Therapeutics (Cambridge, MA)

DecImmune Therapeutics (Cambridge, MA; $4.3M SBIR) said that it has completed a $2.25 million equity financing. .. is looking to develop an antibody therapeutic that reduces tissue damage after a heart attack. [Boston Globe, Feb 26, 13]

&DCL Medical Laboratories ((Indianapolis, IN)

DCL Medical Laboratories (Indianapolis, IN; no SBIR) plans to hire an additional 125 workers at its Northwestside complex, nearly doubling its local work force, to help it keep up with a brisk demand from doctors' offices, pharmaceutical companies and other customers. ... also plans to add 20,000 square feet of commercial lab space as part of a $4.7 million investment. [Indianapolis Star, May 8]

Deca-Medics (Columbus,OH)

SolidWorks (Concord, MA; no SBIR; a unit of (French) Dassault Systèmes) focused on computer aided design, said that one of its customers used SolidWorks software in developing a belt that helps emergency responders administer more effective CPR chest compressions to cardiac arrest victims.  What's more, the life belt from Deca-Medics (Columbus, OH; $1.1M SBIR) was deemed the winning design in the annual NASA Tech Briefs "Create the Future Design Contest," SolidWorks said. [Boston Globe, May 4, 09]  Solid Works founded 1993, bought by Dassault 1997 for stock valued at $310 million. [company website]

deciBel Research (Huntsville, AL)

deciBel Research (Huntsville, AL; $10M SBIR) won a potential 60-month, $172.6M contract to help the Missile Defense Agency develop software and model applications to support ballistic missile defense system operations. [Brenda Marie Rivers, GovConWire, Jun 17, 19] Military software makes useful R&D and sometimes build government confidence in a contractor, especially one near the flagpole. Which gets the gov R&D done with little chance of technical failure, but opens few windows for innovation with long range consequences. It all comes from Congress's wish to help small biz without annual appropriations wrestling.   

Deciphera Pharmaceuticals (Waltham, MA)

Deciphera Pharmaceuticals (Waltham, MA; no SBIR) down 75% [Nov 5, 21] announced top-line results from the INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. The study did not meet the primary endpoint of improved progression-free survival (PFS) compared with the standard of care sunitinib. [company press release, Nov 5, 21]

FDA approved Deciphera Pharmaceuticals (Walham, MA; no SBIR) drug ripretinib (Qinlock), a new treatment intended for patients with a gastrointestinal stromal tumor (GIST) who have failed at least three previous treatments. [Sarah de Crescenzo, xconomy.com, May 15, 20]

Deciphera Pharma up 16% Apr 28, 20]

Deciphera Pharmaceuticals has been handed a priority review from the FDA for its cancer drug ripretinib. [Ben Adams, Fierce Biotech, Feb 13, 20]

Deciphera Pharma down 16% [Feb 13, 20]

Deciphera Pharma up 80% [Aug 13, 19] Announces Second Quarter 2019 Financial Results "In recent months, we've made substantial progress across our pipeline of novel candidates from our two Phase 3 GIST trials with ripretinib to the addition of DCC-3116, a potential first-in-class autophagy inhibitor aimed at treating mutant RAS cancers," said [CEO]Hoerter. [company press release, Aug 13, 19]

Deciphera Pharma down 18% [Oct 19, 18]

Deciphera Pharmadown 11% [Oct 4, 18]

Deciphera Pharma down 12% [Jun 22, 18]

DeecipheraThera down 17% [Jun 21, 18]

Deciphera Pharma down 14%  [Jun 7, 18]

Deciphera Pharmaceuticals (Waltham, MA; no SBIR, founded 2003, market cap $845M) up 48%  [Jun 4, 18], focused on addressing key mechanisms of tumor drug resistance, announced the presentation of updated data from its ongoing Phase 1 clinical trial of DCC-2618, the company’s broad-spectrum KIT and PDGFRα inhibitor, in patients with gastrointestinal stromal tumors (GIST) and provided additional clinical and regulatory updates on DCC-2618. ....  very encouraging and supports the planned initiation later this year of our Phase 3 trial  [company press release, Jun 2, 18]  announced that it has commenced a proposed public offering of 3,750,000 in shares of its common stock  [company press release, Jun 4, 18] total funding $142M, IPO Sep 2017 [crunchbase.com]

Deciphera Pharmaceuticals (Waltham, MA; SBIR) raised $128 million in an upsized IPO.  Deciphera develops drugs that block kinases, enzymes that play a key role in the growth and spread of cancers. Its lead drug, called DCC-2618, blocks a full range of kinases that drive gastrointestinal stromal tumors, or GIST. The compound is in a Phase 1 clinical trial.  [Frank Vinluan, xconomy.com, Sep 29, 17]

Deciphera Pharmaceuticals LLC (Waltham, MA; no SBIR, founded 2002) is getting a money infusion.  The clinical-stage biotech company has increased the size of its Series B financing deal to over $90 million ... originally closed a $75 million deal. nearly doubling its previous investments to date.  ... specializes in developing advanced kinase inhibitor treatment drugs targeting the tumor cell and the tumor microenvironment [ Dora Grote Kansas City Business Journal, Jan 14, 16]

Deciphera Pharmaceuticals LLC (Waltham, MA; no SBIR founded 2002) clinical-stage biotech company closed a $75 million Series B financing ... to advance its pipeline of a kinase-inhibiting cancer drug ...  previously received $30 million from Eli Lilly in April 2014.   [Dora Grote, Kansas City Business Journal, Oct 20, 15]

Decision Biomarkers (Waltham, MA)

Decision Biomarkers (Waltham, MA; one SBIR) announced today the launch of the Avantra biomarker workstation, along with its Max Biochip 8-plex cytokine immunoassay. ... the first multiplexed immunoassay system that enables nonspecialized technicians to perform complex protein biomarker analyses in both the lab and directly at clinical trial sites. [Chris Reidy, Boston Globe, Jan 18]

Deepwater Wind

Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M;  A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.

Defense Engineering (Beavercreek, OH)

Defense Engineering (Beavercreek, OH; $1M SBIR, 13 employees) landed a $4 million Air Force Research Laboratory contract.  .....   for work on electromagnetic scattering and antenna technology, or EMSAT.  [Joe Cogliano, Dayton Business Journal, Nov 20]

Defense Research Associates (Beavercreek, OH)

Defense Research Associates (Beavercreek, OH; $45M SBIR) landed a $45.6 million contract with the Air Force Research Laboratory.  [John Bush, Dayton Business Journal, Jun 25, 18] Innovation or just good engineering? all in the eye of the contracting parties and the re-election campaigns of Ohio politicians.

Defense Research Associates (Beavercreek, OH; $1.8M previous SBIR, 45 employees) is getting $3.5 million for unmanned aircraft sensor work from the U.S. Air Force. ...   recently awarded $1.5 million SBIR as well as $2 million from the Airborne Sense and Avoid program, managed by the Air Force Life Cycle Management Center. The $1.5 million is a new award and the other is funding under a $23.5 million contract the company won at Wright-Patterson Air Force Base last fall.  ... centers on developing sense-and-avoid capabilities to improve the agility of [drones] and allow them to make collision avoidance maneuvers on their own. [Joe Cogliano, Dayton Business Journal, Mar 20, 15] Sounds like what the AF prefers: sound and safe engineering by firms in the Dayton area around the flagpole.

Defense Research Associates (Beavercreek, OH; $1.8M SBIR, 45 employees) won a $23.5 million [six-year] contract to continue work on a U.S. Air Force sensors project.  ...  includes commercializing technology it previously developed by incorporating collision warning capability into sensors without having to modify aircraft. ....   specializes in electronics and communications equipment research and development,     [Joe Cogliano, Dayton Business Journal, Oct 21, 14]

Defibtech (Guilford, CT)

Defibtech (Guilford, CT; no SBIR), manufacturer of automatic external defibrillators, said that it signed an agreement to be acquired by Tokyo's Nihon Kohden Corporation.  ....  [from 30 employees in 2006] one of the state's 40 fastest-growing technology companies each of the last six years, according to the the Marcum Tech Top 40  [Brian Dowling, Hartford Courant, Nov 13, 12]

Dekkun (Cambridge, MA)

Stealthy, early-stage pharmaceuticals company Dekkun (Cambridge, MA; no SBIR) has raised $9.93 million of a planned $30.5 million equity offering, according to a regulatory filing.  The company was incorporated on Jan. 3 this year, posting its location in Cambridge, and operating out of the office of HealthCare Ventures LLC, a life sciences-focused venture capital firm. It does not yet have a working website.  [Michelle Lang, Mass High Tech, Jan 10, 11]

Delcath Systems

Delcath Systems (NYC and Queensbury, NY; no SBIR) medical device manufacturer,  .... raised $21 million from investors during the first two months of 2013, and wants $50 million more.  [Barbara Pinckney, The Business Review (Albany), Mar 14, 13]

Also IPOing this week is DELCATH SYSTEMS with zero revenue and a $57M loss last year by five employees. It makes a system to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

Delinia (Cambridge, MA)

Delinia 9Cambridge, MA, and San Francisco, CA; no SBIR) raised a $35 million Series A round ...  plans to treat “serious and life-threatening autoimmune diseases,” according to a company statement, though it hasn’t said which ones as of yet.  There are many autoimmune disorders, from rheumatoid arthritis to inflammatory bowel disease and lupus. The common theme is a haywire inflammatory response that causes damage to one part of the body or another—in RA, our joints, and in IBD, our guts  [Ben Fidler, xconomy.com, Sep 14, 16]

Denali Medical (Blaine, MN)

Takeda Pharmaceuticals  (Japan) and Denali Therapeutics (South San Francisco, CA; no SBIR, founded 2015)  announced that they have entered into a strategic option and collaboration agreement to develop and commercialize up to three specified therapeutic product candidates for neurodegenerative diseases. Each program is directed to a genetically validated target for neurodegenerative disorders, including Alzheimer’s disease and other indications, and incorporates Denali’s ATV platform for increased exposure of biotherapeutic products in the brain.   $150 million up front in cash and stock to co-develop up to three drugs for neurodegenerative diseases. [joint companies press release, Jan 5, 18]

Med-tech startup Rotation Medical (Plymouth, MN; no SBIR) which has developed an implant for treating rotator cuff disease, has raised about $5.5 million through the sale of debt, according to a regulatory filing.  ... spun out of venture-backed med-tech incubator Denali Medical (Blaine, MN; no SBIR). ... founded in 2009, raised $10 million in 2011 and received regulatory approval to market its technology in January.[Katherine Grayson, Minneapolis / St Paul Business Journal, Jun 5, 13]  

Dendreon

Mitch Gold, the former CEO of Dendreon, has just gotten some big backing for his latest cancer drug startup.  Alpine Immune Sciences,(Seattle, WA; neither time nor need for SBIR) touting a next-gen method of harnessing our body’s defenses against cancer, has raised a whopping $48 million Series A round. [Ben Fidler, xconomy.com, Jun 13, 16]

Dendreon (Seattle, WA; no SBIR) biotech that developed the prostate cancer drug Provenge, has filed for Chapter 11 bankruptcy protection.  .... was looking at $620 million in debt that was coming due in January 2016. 

Dendreon , the region’s most valuable biotech company of the past couple years, started last week worth more than $5 billion, and ended up yesterday worth about $1.5 billion. Some of this is because there’s panic selling in the overall market, but mostly ,investors ran for the exits after Dendreon said it is fallign short of its sales forecasts of $350 million to $400 million this year because it has had trouble convincing doctors that they can get Medicare reimbursement in a consistent and timely manner.  [Luke Timmerman, xconomy.com, Aug 11, 11]

Dendreon dropped 6.8% after the U.S. government said it would begin a coverage analysis on whether the company's immunotherapy treatment for prostate cancer is "reasonable and necessary."  [Wall Street Journal, Jul 2, 10]

Dendreon CEO sold more than $28 million of company stock in the hours after the U.S. Food and Drug Administration approved the cancer treatment Provenge late last week. ...   Other company officials also sold shares   [Wall Street Journal, May 4]

FDA approved [Dendreon's] Provenge, sometimes called a "cancer vaccine" because it stimulates the immune systems of men with advanced prostate cancer to attack their malignancies [Washington Post, Apr 30, 10]

A decision is due this week on Dendreon's application to bring the country's first cancer-treatment vaccine to market. ... Analysts estimate a course of Provenge will cost between $50,000 and $75,000. As many as 100,000 men a year develop the advanced form of prostate cancer the treatment would initially be prescribed for.[Sandi Doughton, Seattle Times, Apr 25, 10]

Dendreon expects to spend up to $50 million to expand its therapeutic biotechnology processing facility in Morris Plains, New Jersey, the company said Monday in a regulatory filing  [Seattle Times, Jun 22, 09]

Dendreon down 45%.[Apr 28, 09]  Shares of the company hit a 52-week high of 25 earlier in the session, but tumbled shortly before being halted prior to the announcement and never resumed trading.[Wall Street Journal, Apr 29]   Dendreon's experimental immune therapy extended prostate cancer patients' lives by 4.1 months and improved three-year survival by 38 percent, the firm announced today. [Seattle Times, Apr 28]

An experimental treatment that takes an entirely new approach to fighting prostate cancer proved it extends survival in a late-stage study, Dendreon said Tuesday, sparking a leap in its stock price.  [Seattle Times, Apr 15, 09]

Dendreon shares rose from a months-long slumber today after three members of Congress called for an investigation of the FDA's decision not to approve the Seattle company's lead therapy for prostate cancer, Provenge. ... However, it's unlikely that a Congressional investigation will propel Provenge forward, because the interim clinical trial results sought by the FDA might be available before the inquiry reaches any resolution, Latta said. [Seattle Times, Dec 13,07]

Dendreon jumped nearly 14% early [Jul 3, 07] boosted by a scientific articlethat cast positive light on its flagship anti-prostate cancer therapy, Provenge. [Angel Gonzalez, Seattle Times, Jul 3] It ended the day up 7%.

Dendreon plunged 64% after the FDA requested more clinical data to support the effectiveness of the Seattle biotechnology company's prostate-cancer drug, Provenge.  The news was a setback for Dendreon and other companies with treatments that use the body's immune system. Among those stocks, Cell Genesys declined 6.1%; Antigenics lost 12%; and Favrille fell 18%. [Wall Street Journal, May 10]

DeNovo Sciences (Ypsilanti, MI)

  in this year’s Accelerate Michigan business plan competition  DeNovo Sciences (Ypsilanti, MI; no SBIR) won the grand prize of $500,000. [over] nine other finalists on the last day of the competition with its microfluidic-based platform technology that can detect circulating tumor cells earlier and with greater sensitivity than standard biopsy approaches. Winning a runner-up prize of $150,000 was Fusion Coolant Systems, (Ann Arbor, MI; one SBIR), a University of Michigan spin-out that makes an advanced coolant and lubria­tion sys­tem for use in man­u­fac­tur­ing. [Sarah Schmid, xconomy.com, Nov 18, 11]

Deposition Sciences (Santa Rosa, CA)

Defense giant Lockheed Martin has acquired  Deposition Sciences  (Santa Rosa, CA; $500K SBIR, 85 employees, a subsidiary of Advanced Lighting Technologies (Solon, OH;  no SBIR)) that provides thin film coatings   [Emily Mekinc, Washington Business Journal, Jun 19, 14]

DermAvance Pharmaceuticals (Berwyn, PA)

Ben Franklin Technology Partners of Southeastern Pennsylvania invested $2.3 M in 10 companies in its latest round of funding. DermAvance Pharmaceuticals (Berwyn, PA; no SBIR). received the largest investment -- $500,000. ...acquires and commercializes anti-aging products. [Philadelphia Business Journal, Jun 6, 08]

DermBiont (Boston, MA)

Skin microbiome therapeutics company DermBiont (Boston, MA; no SBIR), raised $8.8M in a funding round, according to an SEC filing. [Rowan Walrath, Boston Inno, Jun 11, 19]

Dermira (Redwood City, CA)

Eli Lillyannounced a definitive agreement for Lilly to acquire Dermira (Menlo Park, CA;  no SBIR) for approximately $1.1 billion, in an all-cash transaction. Dermira is a biopharmaceutical company dedicated to developing new therapies for chronic skin conditions. [joint companies press release, Jan 10, 20]

Dermira up 17% [Dec 11, 19] announced that [FDA] has granted Fast Track designation for lebrikizumab, its novel, investigational treatment being evaluated for patients with moderate-to-severe atopic dermatitis. [company press release, Dec 10, 19]

Dermira up 15% [Dec 9, 19]

Dermira up 18%  [Nov 8, 19]

Dermira up 26% [Oct 18, 19] announced that detailed primary results from its Phase 2b dose-ranging study of lebrikizumab are being presented during the 39(th) Annual Fall Clinical Dermatology Conference in Las Vegas, NV. Lebrikizumab is currently being evaluated in a Phase 3 program in adult and adolescent patients with moderate-to-severe atopic dermatitis. [company press release, Oct 17, 19]

Dermira (Menlo Park, CA; no SBIR, founded 2010) up 84% [Mar 15, 19] generated evidence that its treatment for moderate-to-severe atopic dermatitis can pose a challenge to Dupixent. [Fierce Biotech, Mar 18, 19] total funding $130M [crunchbse.com]

Dermira up 10% [Oct 3, 18]

Dermira down 23%  [May 24, 18]

Dermira up 10% [Mar 12, 18]

Dermira up 11% [Mar 6, 18]

Dermira (Menlo Park CA; no SBIR, market cap $1B) down 66% [Mar 5, 18] In a major surprise for Dermira and Wall Street alike, Dermira’s acne drug failed to meet the co-primary endpoints of two important, late-stage clinical trials. .... shares have dropped nearly 63% over the last three months [Emma Court, Market Watch, Mar 5, 18]

Skin treatment developer Dermira (Redwood City, CA; no SBIR) raised its IPO fundraising targets and hit them, raising $125 million.  ...  Despite $68 million in accumulated deficits and no revenue   [Cromwell Schubarth, Valley Business Journal, Oct 3, 14]

Dermira (Redwood City, CA; no SBIR), a biotech company working on treatments for psoriasis and other skin problems, plans to seek up to $75 million in an IPO. ...  has raised about $128 million since it was founded in 2010  [Cromwell Schubarth, Silicon Valley Business Journal, Aug 28, 14]  

Dermira (Redwood City, CA; no SBIR), a development stage biotechnology firm focused on dermatology therapies, raised $35 million in Series B financing [Chris Rauber, San Francisco Business Times, Jun 11, 13]

Dermira (Redwood City, CA; no SBIR). said it has raised $42 million in Series A funding..... for acquisition, development and commercializing dermatology-related therapeutics. ... development stage biotechnology company developing and commercializing new therapies in dermatology, with a lead product in clinical trials for acne. [Silicon Valley / San Jose Business Journal, Oct 20, 11]

Desalitech (Newton, MA)

Desalitech (Newton, MA; ineligible for SBIR) clean water technology company, has landed $11 million in equity funding from a private investment group  ...  brings total funding to date to about $24M ... moved from Israel to Newton last year, recently sold one of its water purification systems to one of the world's largest Coca-Cola bottlers and plans to double its workforce in Newton   [Sara Castellanos, Boston Business Journal, Dec 2, 14]

Descartes Labs (Los Alamos, NM)

Descartes Labs (spinout from Los Alamos NL, Santa Fe, NM; $1.5M SBIR, founded 2014) announcing that it has closed a $20 million round of funding [Ingrid Lunden, techcrunch.com, Oct 11, 19] prior funding $38M [crunchbase.com]

Descartes Labs (Los Alamos, NM; too soon for SBIR) startup that specializes in using detailed satellite imagery of the Earth's surface to track climatic trends, agricultural production and geologic changes has landed $5 million in venture capital, according to a report in the Santa Fe New Mexican.  ... formed by a team of former scientists at Los Alamos National Laboratory  [Mike English, Albuquerque Business First, Dec 1, 15]

Design Knowledge (Fairborn, OH)

Design Knowledge (Fairborn, OH, a stone's throw to WPAFB [company website]; at least 31 SBIR awards for something like $25M typically in management technology, founded 2002) won a seven-year R&D contract with the U.S. Air Force. [John Bush, Dayton Business Journal, Jun 7, 18]

DesignMedix (Portland,OR )

DesignMedix (Portland, OR, housed in the Portland State Business Accelerator; $5M SBIR/STTR, founded 2008) entered into an agreement with [NIH] that will pave the way for first-in-human clinical trials of DesignMedix’s malaria drug DM1157. The agreement  builds on the strong package of preclinical data DesignMedix has developed to prepare its malaria drug for clinical trials. Under the agreement, NIH will sponsor a Phase I clinical trial of DM1157.   [company press release, Apr 10, 17]  received a $350,000 phase I grant award from NIH SBIR [company press release, Apr 4, 16] received a major Phase II STTR [NIH STTR] grant to continue development and manufacture of a new anti-malarial drug.  [company press release, Apr 15, 14]

(Oregon) Gov. Kate Brown announced that five companies would receive a combined $300,000 to fund innovation from Business Oregon, the state's economic development arm, and act as follow-on funding for awards from [SBIR]: DesignMedix (Portland, OR; $1.4M prior SBIR): makers of a drug to improve malaria treatment, $75,000;  Energy Storage Systems (Portland, OR; no SBIR): makers of a new kind of battery for utility-scale energy storage, $75,000;   SupraSensor  (Eugene, OR; no SBIR, founded 2012): makers of a testing device that helps farmers use fertilizer more efficiently, $61,875; NemaMetrix  (Eugene OR; $200K SBIR, founded 2011): makers of an advanced drug screen for cheaper, faster testing, $49,100;  HM3 Energy (Gresham, OR; one SBIR): developers of a technology that converts forest debris into briquettes that can replace coal in power plants, $40,171.  [Mason Walker, Portland Business Journal, Apr 17, 15]

The Portland Seed Fund has emerged as one of the most active early-stage investors in Oregon and with its latest class, the fund has sunk its teeth into companies that are further along in the business lifecycle.The 10 companies completing the PSF accelerator are:
    ActionSprout, which makes tools to help nonprofits better use social media.
    Amplion, which makes biomarker business intelligence software for pharmaceuticals and diagnostic companies.
    Bigleaf Networks, which provides cloud-based networking infrastructure software.
    Crowd Supply, which is a platform for crowdfunding product development.
    CrowdStreet, which is a marketplace and investment platform for real estate development.
    DesignMedix, which develops drugs to fight drug-resistant diseases.
    Elli, which is an online marketplace aimed at wedding planning.
    Lumen Learning, which is a platform for colleges and universities to use courseware based on open education resources.
    Poached Jobs, which provides online tools and a jobs portal for the restaurant and hospitality industry.
    Scratch-it, which is developing audience engagement tools for email marketing.
[Malia Spencer, Portland Business Journal, Apr 9, 15] Nine of the ten are low tech risk projects whose only risk is how well the product will sell, which is just fine for  a quick return (if any) for not much investment.  But no big downstream job and industry creation potential. Which is just fine for private investors, but not for public "market failure" investment.

DesignMedix (Portland, OR;  $1.4M SBIR) a biotech startup with ties to Portland State University, has received nearly $3 million from [NIH] to work on the new [anti-malaria] drug over the next three years.  ...  will share the three-year grant with the chemistry lab of PSU professor David Peyton, who invented the technology and co-founded the company.  [Dennis Thompson, Portland Business Journal, Apr 15, 14]

Detcon (Woodlands, TX)

Detcon (Woodlands, TX; no SBIR) was officially founded in a Houston-area garage in 1983. After years of product development, the Woodlands-based gas-detection technology manufacturer has finally hit a nice stride and is quickly expanding its local operations.  .... was acquired in 2011 by Industrial Safety Technologies, a conglomerate of technology safety companies, Detcon has been able to focus more on its technologies while getting exposure to more international markets. [Molly Ryan, Houston Business Journal, Sep 11, 13]  began commercial activity with its first products in early 1985  [company website] 

DE Technologies (King of Prussia,PA)

DE Technologies (King of Prussia, PA; $7M SBIR) has won a contract worth a little more than $6.9 million from the Office of Naval Research to develop technologies for a small-diameter, shaped-charge warhead, the Defense Department said  [Philadelphia Business Journal, Dec 31, 08]

Devicix (Eden Prairie, MN)

Contract electronics manufacturer Nortech Systems (Wayzata, MN; no  SBIR)  is hoping to capitalize on high demand for health care gadgets by acquiring [Devicix (Eden Prairie, MN; one SBIR, 30 employees, founded 2004)]  that does outsourced design work for large and small medical-device makers. ...    $5.3 million plus sales milestones  [Joe Carlson, Minneapolis Star Tribune, Jun 18, 15]

Dewey Electronics (Oakland NJ)

Low Dollar, More Sales. John Dewey rarely sells his signature line of electronic generators abroad.  But two months ago, the CEO of Dewey Electronics (Oakland NJ; no SBIR) started getting calls from overseas. He asked a Greek government official what had changed.  "I said, 'You guys would generally never talk to us,' " Dewey said. "And he responded, 'With the dollar doing what it is, it's changed the assumptions.' "  [Hugh Morey, northjersey.com, Nov 4, 07]  Now if DOD and NASA would use SBIR for more firms like Dewey and less on modeling turbulence and rocket plumes, US export sales could do more to re-balance the national accounts.

Dexcom (San Diego, CA)

Dexcom ($3M SBIR) bests its 'best year ever' with 27% surge to $2.5B revenue in 2021 [Fierce Biotech, Andrea Park, Feb 11, 2022]

Dexcom down 17% [Mar 16, 20]

DexCom (one SBIR, market cap $14B) up 27%  [Nov 7, 19]

Dexcom, a maker of continuous glucose monitors for people with diabetes, said it will cut 350 full-time jobs in San Diego and Arizona as its shifts some customer support and other functions overseas. [Mike Freeman, San Diego Union Tribune, Feb 22, 19]

medical device maker Dexcom has acquired a University of Virginia software spin-off that develops algorithms for regulating and adjusting insulin delivery for people with diabetes.The purchase price for TypeZero Technologies (CHARLOTTESVILLE, VA; $200K SBIR, 15 employees) was not disclosed. But the deal is not expected to have an impact on Dexcom’s financial results in the short term.  [Mike Freeman, San Diego Union Tribune, Aug 24, 18]

DexCom up 31% [Aug 2, 18] "Q2 was a fantastic quarter for DexCom and demonstrates that CGM adoption is increasing significantly," said Kevin Sayer, DexCom's President and CEO. [company press release, Aug 1, 18]

Dexcom up 13%  [May 3, 18]

Dexcom posted a 30 percent jump in revenue for the March quarter as it prepares for a major launch of its next generation continuous glucose monitors that no longer requires finger pricks for calibration.  [Bradley Fikes, San Diego Union Tribune, May 2, 18]

Dexcom  won [FDA]regulatory approval for its latest continuous glucose monitoring system that eliminates the need for finger pricks and is nearly one-third smaller than its current wearable sensor for diabetes patients.  [Bradley Fikes, San Diego Union Tribune, Mar 29, 18]

DexCom down 10% [Jan4, 18]

DexCom inks a development agreement with Eli Lilly  to include Dexcom Continuous Glucose Monitoring (CGM) into Lilly's diabetes ecosystem. The companies plan to combine Lilly's smart insulin delivery devices and Dexcom CGM as a comprehensive solution to improve diabetes management. Clinical studies will begin next month. Financial terms are not disclosed.  [Douglas W. House, SeekingAlpha.com, Nov 21, 17]

DexCom down33% [Sep28, 17]

Dexcom (San Diego, CA; $100K SBIR in 2001 in Wisconsin, founded 1999, market cap $6.3B, 1900 employees), manufacturer of continuous glucose monitoring for patients with diabetes, has expanded into a new manufacturing facility in Mesa. The 180,000-square-foot facility will support the company's global manufacturing operations and is projected to create more than 500 jobs over the next several years. [Angela Gonzales, Phoenix Business Journal, April 14, 17] ...  IPO 2005  ...  based on the groundbreaking research of Dr. Stuart J. Updike and George P. Hicks in 1967—implantable, long-performing glucose sensors that the body would not reject.   [company website]

Medical-device maker DexCom is designing an app that will display readings from its diabetes glucose monitor on Apple’s smartwatch, giving the watch an early foothold in the health-care market.  ... Apple declined to comment. The company hasn’t accepted any apps for the coming watch yet but has provided guidelines and code to developers for creating apps for it.   [Kate Linebaugh, Wall Street Journal, Feb 8, 15] 

DexCom  up 14% [Nov 7, 14]

DexCom up 14% [Aug 7, 14]

Dexcom up 45% [Nov 7, 13]

Dexcom up 21% [Aug 8, 13] revenues up 65% [utsandiego.com]

DexCom,which makes continuous glucosemonitoringdevices for patients with diabetes, acquired SweetSpot Diabetes Care (Portland,OR; no SBIR) health IT company. DexComsaid it will pay as much as $8.5 million in payments over time for SweetSpot, which developed a cloud-based service that helps process data from monitoring devices. [Bruce Bigelow, xconomy.com, Mar 2, 12]

Dexcom  down 20% [Nov 3, 11] after the company reported quarterly earnings

DexComdown18% [Aug4, 11]

Dexcomdown 22%[Nov5,

10]

Blood-sugar-monitor maker DexCom (San Diego, CA; one SBIR in Wisconsin)  said it plans to sell 3.5 million shares of common stock to raise money for working capital. [San Diego Union Tribune, Jan 14, 10]

Dexcom up 10% [May29,09]

Dexcom   up12%[May18,09]

Dexcom up12%[Mar23,09]

Dexcom up 10%[Mar10,09]

Dexcom down 11%[Mar2,09]

Dexcom up 12%[Feb11,09]

Dexcom  up 11% [Feb 6,09]

Dexcom down 13% [Jan20,09]

Dexcom up 12% [Jan16,09]

Dexcom up 19%[Jan5,09]

Dexcom down 16%[Dec18,08]

Dexcom down 11%[Dec15,08]

Dexcom up 11%[Dec12,08]

Dexcom up 10%[Dec8,08]

Dexcom up 10%[Dec5,08]

Dexcom up 50%[Dec4,08]

Dexcon up 12%[Oct28,08]

Dexcom down 10%[Oct15,08]

Dexcom  up 25%[Oct 13, 08]

Dexcom down 18%[Oct9,08]

Dexcom down 10%[Oct7,08]

Dexcom up 10%[Jul22,08]

Dexcom up 10%[Jul11,08]

Dexcom up 11%[Jun13,08]

Dexcom up 13%[May12,08]

Dexcom up 21%[Apr18,08]

Dexcom up 16%[Apr7,08]

Dexcom down 10%[Mar28,08]

Dexcom down 13%[Mar10,08]

Dew & Ken Group (Madison, WI)

A Wisconsin company that has opened two new subsidiaries in China is hoping to play a big role in LED development. James Sun, company founder, worked on developing the technology for high-power LEDs while working at Lumileds, a Silicon Valley spinoff of HP ... Sun's company, Dew & Ken Group (Madison, WI), employs 20 people worldwide and has installed more than 260 LED streetlights in China, with orders for another 2,800.   [Thomas Content, Milwaukee Journal Sentinel, Jun 7, 08]

Dharmacon (Lafayette, CO)

The Scientist strives annually to identify the latest and greatest tools, technologies, and techniques to hit the life-science landscape. This year’s selection includes Quanterix (Lexington, MA; $200K SBIR) brought its Simoa biomarker detection technology to the lab bench, launching the compact SR-X system; Promega (Madison, WI; $5M SBIR) new protein detection system excels at measuring protein levels across the cell; and Dharmacon (Lafayette, CO; $1.6M SBIR) launched on the market in June 2017, instead provides users with an arrayed library of synthetic crRNA guides with a “one-well-per-gene” format, allowing for a much subtler assay. [The Scientist, Nov 30, 17] .

Diagnostic Biochips (Columbia, MD)

[A] sensor, being developed by Diagnostic Biochips  (Columbia, MD, no SBIR, founded 2011), sends real-time data about brain activity to researchers using a wireless signal. ... more accurate than MRI scans and less invasive than blood tests  ... plans to soon launch an angel investing round to raise $1.5 million.  ....among the 41 startups moving forward in the state’s InvestMaryland Challenge. ....  work has been primarily funded through a stream of National Institutes of Health grants (a total of $1.6 million over two years).  Diagnostic is not yet profitable. The company’s total funding so far includes $150,000 from angel investors, a $100,000 Maryland Technology Development Corp. award and investments from its founders.   [Sarah Gantz,  Baltimore Business Journal, Feb 19, 14]

 The Maryland Technology Development (Tedco) has invested $1.1 million in 14 state startups.The grants were made through the organization's Technology Commercialization Fund. ... toward advancing the each company's technology and product commercialization efforts. Common Curriculum LLC, Diagnostic Biochips Inc. and Firejack Inc. were each awarded $100,000.  • Authentik Solutions LLC; Brain Sentry LLC; Clear Guide Medical LLC; ConverGene LLC; Cordex Systems LLC; Pregmama LLC; SameGrain, Inc; TimberRock Energy Solutions, Inc. and Vasoptic Medical, Inc. each received $75,000. • Magpie Sensing LLC was awarded $74,990  • Weinberg Medical Physics LLC received $60,000  [Baltimore Business Journal, Jul 19, 13]

Diagnostic Hybrids (Athens, OH)

Quidel (San Diego, CA; no SBIR, founded 1979)  said it has received regulatory clearance to sell a test to detect respiratory viruses.   .....In early 2010,  acquired Diagnostic Hybrids (Athens, OH, $500K SBIR) as part of a continued focus on increasing its research and development efforts to accelerate the rate of new product introductions.  [Bradley Fikes, utsandiago.com, Mar 12, 13]

diagnostic test maker Quidel (San Diego, CA; one SBIR) announced plans to buy the privately held Ohio diagnostics company Diagnostic Hybrids (Athens, OH; $500K SBIR) for about $130 million. [Thomas Kupper, San Diego Union Tribune, Jan 12, 10]

DiaMedica (Plymouth, MN)

Diamedica Thera up 22% [Jun 19, 20]

Diamedica Thera up 19% [Jun 17, 20]

Diamedica Thera up 16% [Feb 18, 20]

Diamedica Thera up 30% [Jun 20, 19] announced that DM199 (recombinant KLK1) was observed to be safe and well tolerated with no drug-related serious adverse events (SAEs), consistent with earlier DM199 studies in healthy volunteers. [company press release, Jun 19, 19]

Diamedica Therapeutics (Minneapolis, MN; no SBIR) up 19% [Jun 17, 19]

DiaMedica Therapeutics (Plymouth, MN; no SBIR) announced the [IPO] pricing tp raise$16M. [company press release, Dec 7, 18]

Diamedica Thera down 23% [Dec 7, 18]

DiaMedica (Minneapolis, MN; no SBIR, founded Y2K) files to raise $15M through public offering toward further development of its drug candidate, DM199 [Katharine Grayson, Minneapolis/St Paul Business Journal, Nov 12, 18] total prior funding $4M [crunchbase.com]

DiaMedica Therapeutics (Plymouth MN; no SBIR), a biopharmaceutical company focused on the development of DM199 (recombinant human KLK1),  announce it has completed a private placement for gross proceeds of approximately $2M [company press release, Apr 21, 17]

Asian investors have entered into a two-part, $4 million investment deal with DiaMedica  (Plymouth, MN; no SBIR) over an experimental drug it produces to treat acute ischemic strokes.  ...  According to DiaMedica’s chief scientific officer Todd Verdoorn, DM199 will be placed in competition with a similar drug manufactured and sold in China. Both products use a protein known as killikrein to improve blood flow within the area of the brain that is experiencing a stroke.   ...  the Chinese version [backed by Takeda Pharmaceuticals] is extracted from urine  while DiaMedica’s is a synthetic product made in a lab. To that effect, [CEO] Pauls believes DiaMedica’s drug is comparatively less expensive and safer than the urine-based formula.  [Sam Schaust, Twin Cities Business,  Jul 18, 16]

Diamond Foundry (San Carlos, CA)

CVD diamond revives.  Diamond Foundry (San Carlos, CA; no SBIR) is not the first company to try to use chemical vapor deposition, to grow diamonds by depositing layers of carbon atoms in a high-energy plasma field.  ....  spent years developing a new manufacturing technique based on a plasma source with a new “shape” that is 10 times as powerful as what has previously been used by manufacturers of synthetic diamonds, R. Martin Roscheisen, a founder of Nanosolar  (San Jose, CA; $1.7M SBIR) said.   By modifying the shape of the plasma field to what he described as a pancake, the group was able to make the reaction that formed the diamond structure more efficient  ...  the founders of Nanosolar, a large start-up that raised about half a billion dollars in its first six years, began exploring ways to build that would apply their expertise to new technologies. ...   A group of engineers and scientists, led by , announced that they had developed an advanced approach to making diamonds, using technology derived in part from making silicon chips and solar cells, to be used by a new company.   [JOHN MARKOFF, New York Times, Nov 11, 2015]  SDIO/BMDO/MDA SBIR funded several CVD diamond projects starting in the late 1980s.

Diatomix (Beaverton, OR)

With assistance from the SBIR/STTR Support Center operated by Oregon BEST, two Oregon start-up companies [won] $450,000 in [NSF SBIR] [Oregon Best website]    Gadusol Laboratories (aka Seaceuticals, Corvallis, OR; no prior SBIR, founded 2017) $225K to advance a technology for producing UV blocking compounds found in marine life that can be used in environmentally friendly, all natural sunscreens, from gadusol that's been found in fish and their eggs at Oregon State U.  Diatomix (Beaverton, OR; no prior SBIR, founded 2015) $225K has developed a patent-pending, bio-engineered smart material that improves indoor air quality by adsorbing and then breaking down hazardous, airborne volatile organic compounds (VOCs) [with] patent pending photo-catalytic product actively and continuously degrades VOCs in the air by turning them into harmless carbon dioxide and water. [company website] $130K raised 2017 [pitchbook.com]

Dicerna Pharmaceuticals (Cambridge, MA)

Dicerna Pharmaceuticals (Lexington, MA; $5.7M SBIR) up 79% [Nov 18, 21] announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk (Denmark) will acquire Dicerna, a biopharmaceutical company focused on the development of investigational ribonucleic acid interference (RNAi) therapeutics, for $38.25 per share in cash, which represents a total equity value of $3.3 billion [company press release, Nov 18, 21]

Dicerna Pharmaceuticals (Lexington, MA; $5.7M SBIR) down 28% [Aug 6, 21] announced positive top-line results from the Company's PHYOX(TM)2 pivotal clinical trial of nedosiran, which is in development as a once-monthly treatment for primary hyperoxaluria (PH), a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. [company press release, Aug 5, 21]

Dicerna Pharma up 17% [May 11, 20]

Dicerna™ Pharmaceuticals (Lexington, MA; $3M SBIR) and Novo Nordisk A/S [Denmark] announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. ... Dicerna will receive: An upfront payment of $175 million, $50 million equity investment in Dicerna at a premium, $25 million annually during each of the first three years of the collaboration, contingent on Dicerna delivering RNAi molecules for a defined number of targets, up to $357.5 million per target in development, regulatory, and commercialization milestone payments, plus tiered royalties on product sales ranging from the mid-single-digits to mid-teens. [joint companies press release, Nov 18, 19]

Dicerna Pharmaceuticals (Cambridge, MA; $3M SBIR) announced a research collaboration and licensing agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to develop novel therapies for the treatment of chronic hepatitis B virus (HBV) infection using Dicerna’s proprietary GalXC™ RNAi platform technology. will receive $200 million in an initial upfront payment and may be eligible to receive up to an additional $1.47 billion over time for the achievement of specified development, regulatory and commercial milestones. [company press release, Oct 31,19]

Eli Lilly teamed with  Dicerna (Cambridge,MA; $2.2M SBIR, founded 2007) in a wide-ranging deal to co-develop RNAi medicines for pain, and cardiometabolic and neurodegenerative diseases. Lilly will pay Dicerna $100 million up front and make a $100 million equity investment in the company at an unspecified premium. The agreement includes another $350 million in downstream payments, plus royalties, but those will only materialize if the programs in the collaboration progress. [Ben Fidler, xconomy.com. Oct 29, 18]

Alexion Pharmaceuticals and Dicerna Pharmaceuticals (Cambridge, MA; $2.2M SBIR, founded 2007, total funding $295M [crunchbase.com] announced a collaboration to discover and develop RNA interference (RNAi) therapies for complement-mediated diseases. Dicerna will receive an immediate upfront payment of $22 million, with Alexion making a concurrent $15 million equity investment in Dicerna at a premium to market as of the collaboration effective date. [joint companies press release, Oct 24, 18]

Dicerna Pharma up 14% [Sep 7, 18]

Dicerna Pharma (Cambridge, MA; $2.2M SBIR) down 18% [Sep 6, 18]

Dicerna Pharma (Cambridge, MA; no SBIR, founded 2007, IPO 2014) up 18% [Apr 20, 18] announced [it] resolved all litigation with Alnylam Pharmaceuticals. ... allows Dicerna to advance all of its key and planned pipeline programs while maintaining a strong balance sheet. [company press release, Apr 19, 18] total funding $295M; develops therapeutic agents in various disease areas based on dicer substrate technology platform. [crunchbase.com]

Boehringer Ingelheim (Germany) and Dicerna Pharmaceuticals (Cambridge, MA; no SBIR, founded 2007), a leading developer of investigational RNA interference (RNAi) therapeutics, announced a research collaboration and license agreement to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases. The partnership will initially focus on nonalcoholic steatohepatitis (NASH), a devastating, chronic liver disease for which there is no approved treatment option.  [joint companies press release, Nov 2, 17]

In 2006 Merck paid $1.1 billion for Sirna Therapeutics (no SBIR), a biotechnology firm reckoned to be a leader in the field. Roche and Novartis also made big investments around the same time. RNAi, it seemed, was going to take the pharmaceutical world by storm.  But siRNAs, so attractive in theory, proved impossible to tame in practice. Roche ended its work in 2010. Novartis and Merck followed suit in 2014. Nevertheless, a clutch of biotechnology companies are still working on the idea, and some of them now think they have cracked it. Chief among them are Alnylam and Dicerna (Cambridge, MA; no SBIR). These firms have, they believe, overcome one of the problems that caused RNAi to fall so deep into the trough of disillusionment—getting siRNA molecules across cell membranes to where they are needed. [The Economist, Oct 17, 15]

Dicerna Pharmaceuticals  (Watertown, MA; no SBIR), which has its own proprietary approach to silencing disease-related genes through RNAi, is announcing today it has raised $60 million in a Series C round of venture financing. ... now gives Dicerna $110 million in raised venture funds  ... Rather than engineering small RNAi molecules in the way that, say, Alnylam does, Dicerna makes them a little bit longer, which enables them to act a step earlier in the gene-silencing process, and thus potentially be more potent and last longer in the body. This, in turn, could mean that Dicerna could give its drugs in lower doses, produce them for less money, and administer them with fewer shots.  [Ben Fidler, xconomy.com, Aug 2, 13]

Dicerna Pharmaceuticals (Watertown,MA; no SBIR) said that Kyowa Hakko Kirin Co. Ltd., or KHK, has elected to advance its first collaborative oncology candidate from the research stage into formal development studies, a move that triggers a $5 million milestone payment for Dicerna. [Chris Reidy, Boston Globe, Dec 19, 11]    venture-backed RNA interference (RNAi) company developing novel therapeutic agents and related drug delivery systems in multiple disease areas based on its proprietary Dicer Substrate Technology™ platform and Dicer Substrate siRNA (DsiRNA) molecules. Dicer Substrate Technology is a next generation RNAi approach that results in greater potency, longer duration of action and enhanced delivery potential, differentiating it from other RNAi approaches [company website]

Dicerna Pharmaceuticals (Watertown, MA; no SBIR) has added $4 million in a second close of its Series B financing, bringing the round to $29 million. ...  drug delivery systems are built around the enzyme Dicer, which is used for gene silencing in generating drug candidates with greater potency and longer action duration than earlier RNAi approaches. [Mass High Tech, Oct 21, 10]

Dicerna Pharmaceuticals (Watertown, MA; no SBIR) RNA interference platform development company, has closed a $25 million Series B funding round ...  support the company’s oncology-focused program and its drug delivery systems [that are]  built around the enzyme Dicer, which is used for gene silencing in generating drug candidates with greater potency and longer action duration than earlier RNAi approaches ... in January it announced it had entered into a research collaboration and licensing deal with Japanese biopharmaceutical firm Kyowa Hakko Kirin Co. Ltd. for up to $124 million.   [Michelle Lang, Mass High Tech, Aug 11, 10]

teaming up to collaborate on some research-and-development work ... are Archemix (Cambridge, MA; $2M SBIR) focused on commercializing aptamer therapeutics, and Dicerna Pharmaceuticals (Watertown, MA; no SBIR) seeking to use RNAi gene-silencing technologies to develop novel drug treatments  [Boston Globe, Jul 21, 09]

Diffusion Pharma

Diffusion Pharma down 27% [Mar 29, 17]

Diffusion Pharma (Charlottesville, VA; no SBIR) up 81% [Mar 28, 17]

Diffusion Pharma up 176% [Jan 9,17]

Difusion Technologies (Austin TX)

DiFusion Technologies (Austin, TX, no SBIR) a start-up medical device company, is gearing up to launch a flagship product that will target the orthopaedic market at the same time it's raising additional capital.  Dr. Matthew Geck, founder and board member of DiFusion, said the company will release a medical device this year capable of killing 650 types of bacteria, including antibiotic-resistant bacteria such as MRSA (also known as “Superbugs”), in local surgical wounds for up to four weeks following surgery.  .... plans to seek between $2 to $3 million in its Series A round of funding in early 2009, [Austin Business Journal, Jan 6, 09]

Digene

OpGen (Gaithersburg, MD; no SBIR) filed to go public in hopes of raising as much as $37.4 million. ...  working to develop diagnostics to address the threat of antibiotic resistance.  ...  describes itself as an "early commercial-stage company using molecular testing and bioinformatics to assist health care providers to combat multidrug-resistant bacterial infections."  ...  led by CEO Evan Jones, who co-founded Digene  ($1.3M SBIR), a genomics company well known to local biotech watchers during Montgomery County's "DNA Alley" heyday of the late 1990s and early aughts. Digene was acquired by Qiagen NV in 2007 for $1.6 billion.   [Jeff Clabaugh, Washington Business Journal, Mar 3, 15]  

Digirad (Poway, CA)

Digirad down 26% [Mar 10, 20]

Digirad (San Diego, CA; $1M SBIR) up 114% [Mar 6, 20] announcd quarterly and year-end financial results

Digirad (Suwanee, GA; $900K SBIR in 1990s California) won a potential 10-year, $100 million contract from the Defense Logistics Agency to supply computed tomography imaging equipment devices to U.S. service branches and federal civilian agencies.  [Ramona Adams, govconwire.com, Jul 11, 17]

Digirad  (Suwanee GA; $1M SBIR two decades ago in CA) down 10%  [Nov 16, 15]

Digirad  down 15% [Nov 25, 13]

Digirad up 15% [Nov 11, 13]

Digirad (Poway, CA; $1M SBIR) said the FDA gave the company approval to market Ergo, a nuclear imaging camera system for hospitals that’s smaller and more portable than existing hospital systems. [Bruce Bigelow, signonsandiego, May 13, 10]

Digirad down 18% [Apr 24, 08]

Digirad down 13% [Mar 17, 08]

Digirad down 10% [Jan 23, 08]

Digirad down 18% [Jan 8, 08]

Digirad up 16% [Nov 26, 07]

DigiSight Technologies (Portola Valley, CA)

DigiSight Technologies (Portola Valley, CA; no SBIR) said it has raised a $7.8 million B round to pour into mobile technology that lets eye doctors monitor their patients’ sight between visits.  [Alex Lash, xconomy.com, Feb 12, 15]

Digital Fusion (Huntsville, AL)

Dialing for Dollars.  [Stewart Hall] decided to create a government contractor nearly from scratch. He assembled a group of investors, many of them fellow lobbyists. Together they bought a 25% stake in Huntsville, Ala.-based Digital Fusion Inc., a small technology-consulting company on the verge of bankruptcy. It did little business with the government, so Mr. Hall set out to beef up its defense-contracting business. Today, it mainly helps government agencies use computer technology for tasks ranging from budget analysis to missile engineering. That happens to be a growing part of the government's large defense operations in Huntsville, the home terrain of Sen. Shelby.... It has snagged more than $85 M in federal software contracts. In the two years since Mr. Hall invested in the company, revenue tripled to $20.9 M. The stock shot up as high as $3.75 earlier this year from a low of 15 cents before Mr. Hall showed up. [Brody Mullins, Wall Street Journal, Oct 7] Digital Fusion now has a Phase 1 STTR from the Army, but the public record will never show whether any political influence was used to win it.  And why does a company with $85M in federal software contracts and an in with an influential Senator need nursery funding?  For the same reason that other SBIR firms with $200M in past SBIRs, it's easy money once you learn how.

Digital Lumens (Boston, MA)

Digital Lumens (Boston, MA; no SBIR) said it has raised a $10 million round of funding from existing investors amid growth in installations for its Intelligent LED Lighting System. ....  brings Digital Lumens to at least $35 million since its founding in 2008. [Kyle Alspach, Boston Business Journal, Jan 9, 13]

Digital optics

Light Stopped. Two physicists slowed light by trapping it in a really cold crystal of praseodymium-doped yttrium-silica crystal. Phil. Hemmer at the AFRL and Selim Shahriar at MIT sent the news to Physical Review Letters while the try stretch the hold time to tenths of a second. [facts from Business Week, Nov 19]. Sharhiar also has commercial dreams, although not with halted light. from an SBIR Phase 2 from BMDO in his company Digital Optics.

Dignify Therapeutics (Research Triangle Park, NC)

Real seed investment. On average, every dollar N.C. Biotech loans to young life science companies is met with $118 in additional funding to those firms from disease philanthropy and government grants, angel and venture investment and other financial support, according to the center. Every grant dollar is met with an average $28 in additional funding.  ...  loans and grant made by the Biotech Center in the second fiscal quarter:      $50,000 in a Company Inception Loan to Spyrix (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, developing a treatment for cystic fibrosis. The loan is intended to help position the company for outside investor and foundation funding and to help with preclinical development of its product.       $75,000 to Eppin Pharma (Chapel Hill, NC; no SBIR), UNC-Chapel Hill spinout, to help in its development of a reversible, oral, non-hormonal male contraceptive pill. This money will help support toxicology and other testing of the company's lead drug candidate and help position Eppin to seek additional funding from investors, federal grants and foundations.       $250,000 to Dignify Therapeutics (Research Triangle Park, NC; one SBIR, eight employees), developing a novel drug to help people with spinal injuries clear their bladders and bowels when they choose to do so. The loan will support studies of the drug's safety and help Dignify develop a final formulation of the remedy, for use in clinical trials.      $458,000 to Bioptigen  (Morrisville, NC; $2.9M SBIR), to support late-stage development and clinical testing needed for FDA approval of its intrasurgical optical coherence tomography device for real-time guidance of ophthalmic surgery.       $500,000 to Baebies (Durham, NC; no SBIR),  to help it develop its products to diagnose health risks in infants from a single dried blood spot, using a technology called digital microfluidics. This loan supports the company's newborn screening tests for three devastating disorders (Pompe, biotinidase deficiency and galactosemia).  [Jason deBruyn,Triangle Business Journal, Feb 4, 15]   SBIR has no chance of such rewarding results because about three-fourths of the money is spent by agencies that just want what they can use for their own purposes with no regard for whether there is any widespread economic payoff, nor any payoff to society. SBIR can hide these facts behind privacy of private business whihc is OK with Congress as long as the small biz get the prescribed handouts.

Dignify Therapeutics (Research Triangle Park, NC; one SBIR, eight employees) drug developer took a big step forward by raising more than $3 million in venture capital, the first venture financing in the company's history. ...  is developing a drug to help people with spinal injuries clear their bladders and bowels when they choose to. [Jason deBruyn,Triangle Business Journal, Feb 4, 15]

Dimension Inx (Chicago, IL)

Dimension Inx (Chicago, IL; no SBIR, founded 2017) a next-generation biofabricationcompany developing regenerative medical implants that repair tissues and organs, announced that it has raised $3.175M to close its Series Seed financing round, [to] support the commercial development and FDA approval of the company’s first therapeutic implants for facial reconstruction in patients followingtrauma as well as those with dentalma lformations due to congenital defects or aging. [company press release, Nov 10, 20]

Dimension Technologies (Rochester, NY)

PTC Thera down 11% [Oct 3, 17]

RegenxBio  has opted to back away from a deal to buy Dimension Therapeutics after the biotech received a better buyout offer. RegenxBio said it doesn't plan to match, or best, the unsolicited $6-per-share price that Ultragenyx Pharmaceutical is now offering to Dimension Therapeutics that's struggled with its pipeline in the last year. (Washington Business Journal, Oct 2, 17)

Dimension Technologies (Rochester, NY; $6M SBIR) has been featured in a NASA technical publication on Aviation and Air Transportation.  ... features DTI’s DTI ROC3D technology that allows users to view full-resolution 3-D images without the need for glasses or headsets, the company said. The firm, part of the Rochester Institute of Technology’s Venture Creations, manufactures and licenses product for computer and video displays.    [KERRY FELTNER, Rochester Business Journal, Feb 2, 17]

Dimension Therapeutics (Cambridge, MA)

Dimension Therapeutics (Cambridge, MA; no SBIR) up 40% [Sep 18, 17]  a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, today confirmed that it has received a non-binding, unsolicited proposal from Ultragenyx Pharmaceutical  (no SBIR) to acquire Dimension for $5.50 per share in cash. But As announced on August 25, 2017, Dimension entered into a definitive merger agreement with REGENXBIO under which REGENXBIO will acquire Dimension in an all-stock transaction.  [company press release, Sep 18, 17]

Dimension Therapeutics (Cambridge, MA; no SBIR) agreed to be acquired by RegenxBio (Rockville, MD; no SBIR), the gene therapy developer that originally helped form the company four years ago. RegenxBio will pay approximately $86 million. By comparison, Dimension went public at $13 per share in 2015. Dimension’s closing stock price on [Aug 24] was $1.20. [xconomy.com, Aug 25, 17]

Dimension Therapeutics (Cambridge MA; no SBIR) down 17% first day from its IPO that raised  $72M  [Wall Street Journal, Oct 22, 15]

Fidelity Biosciences, a venture capital firm that is a subsidiary of the parent company of Fidelity Investments, and REGENX Biosciences announced the formation of Dimension Therapeutics (Cambridge, MA) gene therapy company focused on developing novel treatments for rare diseases such as hemophilia. [Chris Reidy, Boston Globe, Oct 31, 13]

Dimien (Amherst, NY)

Dimien (Amherst, NY; $900K SBIR) clean tech manufacturer of ceramics and inorganics that are used as additives in laminates, inks, coatings, plastics, and other ceramics [company website] was a Finalist in the 43North startup competion for $1M. The winner was SparkCharge (Syracuse, NY; no SBIR) a Syracuse University spinoff that offers a portable electric-vehicle (EV) charging unit   [Eric Reinhardt, Central NY Business Journal, Oct 5, 18].

DioGenix (Gaithersburg, MD)

Montgomery County [MD, a competitor for America's richest county] will dole out $500,000 to investors in 10 life sciences companies through its coveted biotech tax credit, a fifth of which will go to backers of diagnostics company DioGenix (Gaithersburg, MD; no SBIR)  ... piggybacks on the $3.5 million in tax credits from the state to those same 46 investors. The incentives are tied to a total $7 million in private biotech investments in the county last year. Also receiving the credits are backers of 20/20 GeneSystems (Rockville, MD; $4.6M SBIR, incl one of $3.3M),  Alper Biotech LLC, American Gene Technologies International Inc., BeneVir Biopharm Inc., ConverGene LLC, Creatv MicroTech (Potomac, MD; $11.6M SBIR)., Rafagen Inc., Sequella (Rockville, MD; $10.3M SBIR). and SynAm Vaccine. [Bill Flook,Washington Business Journal, Feb 28, 14]

Directed Manufacturing (Austin, TX(

Directed Manufacturing (Austin, TX; no SBIR, founded 2007) has developed the largest 3-D printed rocket engine component NASA has tested. ...  the rocket engine injector that was tested during an engine firing that generated a record 20,000 pounds of thrust [Christopher Calnan, Austin Business Journal, Aug 28, 13]

Directed Perception (Burlingame, CA)

Flir Systems said it has acquired Directed Perception (Burlingame, CA; no SBIR) for $20 million in an all-stock deal. ... Directed Perception makes pan-tilt motion control systems for commercial and military markets. [Portland Business Journal, Dec 27, 09]

Disc Dynamics (Eden Prairie, MN)

Disc Dynamics  (Eden Prairie, MN; no SBIR), a once-promising medical device start-up that raised about $65 million from investors, has shut down and is selling off its assets.  ...  developed a minimally invasive technique to treat low back pain, failed to win a go-ahead from the FDA to conduct a pivotal clinical trial.  [Minneapolis Star Tribune, Feb 5, 10]

Disc Dynamics (Eden Prairie, MN; no SBIR) was founded in 2000 to develop the Dascor technology and has received $65 M from private and venture capital investors.   Disc says  The potential market for devices and related biologics treating back maladies is estimated to be $4.1B in the United States this year, and is expected to grow 20% annually.$10M of the VC money came from Steve Stassen who sold his previous company SpineTech to a Swiss company in 1998 for $600M, and Stassen went on to help found the venture capital firm Split Rock Partners. But he never forgot the promise of the Dascor technology.   [Janet Moore,Minneapolis Star-Tribune,Jun 11] with that scale knowledgeable financing, a companydoes not need, cannot afford, the slow nickels and dimes of sbir.

Disc Medicine (Cambridge, MA)

Disc Medicine (Cambridge, MA; no SBIR), a new biotech that aims to treat anemia caused by a variety of blood disorders, launched out of Cambridge, MA venture firm Atlas Venture on Tuesday with $50 million. The company is developing drugs to impact hepcidin, a liver hormone that helps the body regulate iron absorption. [Sarah de Crescenzo, xconomy.com, Oct 29, 19]

Discovery Genomics (Minneapolis, MN)

gene therapy biotech startup Immusoft (Seattle, WA; one SBIR, founded 2009) has acquired Discovery Genomics  (Minneapolis, MN; $5.5M SBIIR).  With the acquisition, Immusoft gets a license to use Discovery Genomics’ Sleeping Beauty Transposon System, which can deliver genes into cells without using a virus, which is less expensive and more scalable than using a virus, said Matthew Scholz, CEO and founder  [Greg Lamm, Puget Sound Business Journal, Mar 9, 16]

Discovery Labs (Warrington, PA)

 Discovery Laboratories (Warrington, PA; one SBIR) changed its name to Windtree Therapeutics. [John George,  Philadelphia Business Journal , April, 18, 16]

Discovery Laboratories (Warrington, PA; one SBIR), closed a $40M stock offering to fund late-stage testing of its aerosolized surfactant replacement therapy for respiratory distress syndrome in infants born prematurely.   [John George, Philadelphia Business Journal, Jul 22, 15]

Discovery Laboratories (Warrington, PA; one SBIR in Y2K) was awarded [NIH SBIR] valued at up to $3 million to support the company’s development of a potential new treatment for radiation-induced lung injuries.  ...    was awarded $1 million and is eligible to receive an addition $2 million over the next three years ... The company’s lead product, Surfaxin, is a synthetic surfactant product used to prevent respiratory distress syndrome in infants born prematurely. The drug was approved by the Food and Drug Administration in 2012, and launched last year.   [John George, Philadelphia Business Journal, Oct 1, 14] 

Discovery Laboratories (Warrington, PA; one SBIR in Y2K) is planning to raise $50 million in a public stock offering.  .... to support its commercial introduction of Surfaxin, a therapy to prevent respiratory distress syndrome in premature infants.  [John George, Philadelphia Business Journal, Oct 31, 13]

Discovery Laboratories (Doylestown, PA; one SBIR in Y2K) stock soared more than 47 percent Friday morning after the FDA agreed to the company’s updated product specification for Surfaxin. .... has initiated manufacturing of Surfaxin for its planned commercial introduction of the product before the end of the year.   [John George, Philadephia Business Journal, Oct 4, 13]

Discovery Labs  up 11% [Feb 27, 12]

Discovery Laboratories (Warrington, PA; one Y2K SBIR) entered into definitive agreements Friday with institutional investors that will provide the company with gross proceeds of about $11.3 million.  The deal will give the biopharmaceutical company a needed cash infusion following a setback last month when the FDA for the fourth time, delayed making a final decision on the company’s new drug application for its flagship new drug candidate Surfaxin. [Philadelphia Business Journal, May 11, 09]

Discovery Labs down 16% [Apr 29, 08] awaiting FDA approval.

DisperSol Technologies (Georgetown, TX)

DisperSol Technologies, LLC, (Georgetown, TX; no SBIR, founded 2007) secured financing [over $10 million] to expand its drug formulation and GMP manufacturing capabilities for its partnerships with the pharmaceutical industry. ... to develop its own portfolio of proprietary drug products with significantly improved bioavailability profiles [company press release, Feb 3, 16]

Displaytech (Boulder,CO)

Onspan Million Micros(Dec 24) Displaytech (Longmont, CO) shipped its one millionth microdisplay, after 12 months of volume production. The millionth microdisplay shipped was a LightView NTSC Monochrome FLC Video Display, produced specifically for use in electronic viewfinders of digital camcorders.Displaytech specializes in ferroelectric liquid crystal (FLC) displays after about $13M of SBIR over a dozen years.

Displaytech develops second sourceFerroelectric liquid-crystal microdisplay maker Displaytech (Longmont, CO) announced that new primary manufacturing facilities in Nagano, Japan, are now producing its displays. The facility, Miyota Company, is executing all phases of microdisplay production. Rather than working with retrofitted semiconductor machines, Miyota has put together its own microdisplay-specific production machines that include packaging, assembly, thin-film, and vacuum tools. The swing into production will open the door to a difficult-to-reach Japanese customer base, according to Displaytech.

Displaytech HP Alliance(Nov 10) With Enough Money, and Time, and Patience... Hewlett-Packard (not a small firm) says it has an alliance with Displaytech (Boulder, CO) for ferro-electric liquid crystal wherein Displaytech makes the reflective silicon chips and HP does everything else, especially selling them. [Wall Street Journal, Nov 9] The government (SBIR) has pumped $12M or so into Displaytech since 1985 for the FLC stuff as the company's employee count steadily rose from one in 1985 to 45 last year. Is that a good enough return for 13 years of investment, and should government be doing that with a start-up nurturing program? No matter, it's being done with lots of other companies because government doesn't know what else to do with its SBIR money since SBIR has far too much money and far too fragmented a management for any efficient start-up program.

Distributed Energy Systems (Wallingford, CT)

Distributed Energy Systems (Wallingford, CT; $2M SBIR) says that it has filed for Chapter 11 bankruptcy protection. [Mass High Tech, Jun 13]

Divergence (St. Louis, MO)

Last month leading ag-biotech company Monsanto purchased former Larta NSF-CAP1, USDA-CAP, and Ag Innovation Showcase company participant Divergence  (St Louis, MO; $4.4M SBIR) focuses on developing technologies to fight against parasitic nematodes, a pest that costs farmers billions of dollars each year. The company has worked closely with Monsanto since 2004 [LARTA, Mar 9, 11]

Divergence (St. Louis, MO; $2.5M SBIR) said it raised $11.8 million in Series C funding to continue development of its technology to prevent or control parasitic nematode infestations [CleanTech Group release, Feb 16, 09]

Diversified Energy (Gilbert AZ)

BioFuel from Pork.  Two companies, Diversified Energy (Gilbert AZ; formed in 2005) and Velocys (Plain City, OH) , are working together on a portable system that converts coal, natural gas, and biomass into diesel and jet fuel. The military could use the system to convert waste created at military bases--food scraps, paper, wood--into a fuel for military jets and vehicles.  .... Velocys, a subsidiary of Battelle Memorial Institute, was launched in 2001 and has developed a portfolio of 70 patents and received $100 million of investment from industry leading partners, [Pachi Partel-Predd, MIT Tech Review, Dec 21]  In June 2005 Congresswoman Deborah Pryce (R-Upper Arlington) today announced that $21.8M for Defense Department projects in Ohio is included in the FY 2006 Department of Defense Appropriations Bill, pursuant to her requests. In Oct 96  A Congressional appropriation for Velocys’ synthetic fuels project was approved for fiscal year 2007. The latest contract to Diversified Energy is a Phase 1 SBIR.

D.Light

In 2007 Stanford MBAs Sam Goldman and Ned Tozun figured out a safer, cleaner way to provide power to low-resource areas. They started D. Light, (no SBIR) a company that makes portable, rechargeable, solar-powered lights. D. Light manufactures the lights in China and sells them in over 30 countries. It offers three models, which range in price from $10 to $40, depending on the model and the country where it’s sold. The most high-end product, called the S250, provides up to 12 hours of light per day, and includes a cell phone charger. ... has raised $12 million in funding, won’t disclose sales. Tice says that companies like General Electric (which today announced plans to build the largest solar power factory in the United States) have approached D. Light about strategic partnerships.  [Helen Coster, Forbes, Apr 7, 11]

DMC Biotechnologies (Boulder, CO)

Bill Gates's Breakthrough Energy Ventures (BEV) aims to invest $1 billion into radical energy startups capable of drastically cutting global emissions. The investees: QuantumScape (San Jose, CA; no SBIR, founded 2010, total funding $100M) building an all-solid-state battery; Commonwealth Fusion Systems (Cambridge, MA; no SBIR, founded 2017, total funding $65M) nuclear-fusion reactor that uses high-temperature superconductors and aims to be the first fusion system to produce net-positive energy ; Pivot Bio (Emeryville, CA; one SBIR, founded 2010, total funding $17M) microbial solution that can replace nitrogen fertilizers; CarbonCure (Canada, founded 2007, total funding $9M) trapping carbon dioxide in concrete blocks, while endowing them with greater strength than conventional concrete; Fervo Energy (San Francisco, CA; no SBIR) rethinking geothermal power with the help of modern computational models and horizontal-drilling; DMC Biotechnologies (Boulder, CO; $900K SBIR, founded 2017, total funding $2M) tailoring microbes to produce high-value chemicals, including biofuels; Zero Mass Water (Scottsdale, AZ; founded 2014, no SBIR) specialized panels that use solar power and batteries to pull water from the air. [Akshat Rathi, Quartz, Sep 26, 18]

DNAnexus

Among the Technology Review fifty smartest companies: Illumina ($5M SBIR plus acquired firms), Alnylam ($600K SBIR), DNAnexus (one SBIR).  The other quadrillion SBIR winners haven't been as smart as the best. To make the list, a company must have truly innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 12 months. [technologyreview.com, Jun 29]

DNAPrint Genomics (Sarasota, FL)

DNAPrint Genomics (Sarasota, FL),which trades for less than a penny a share and lost $12.3 million last year, has been told by its auditors that it is in danger of going out of business, ... "It's a long shot. That's the game we're in. They're all long shots," said Mark Chalek, chief of business ventures at [its deal partner] Beth Israel Deaconess. ... another frustrating chapter in the development of the drug, a form of erythropoietin invented in the mid- 1990s by Dr. Arthur J. Sytkowski of Beth Israel Deaconess, and known officially as PT-401. His work was financed through grants from the National Institutes of Health and the US Navy. [Christopher Rowland, Boston Globe, Apr 9]

DNAtrix (Houston, TX)

Add another player to the field of developing checkpoint inhibitor drugs: biotech DNAtrix  (Houston, TX; no SBIR) . ... announced a partnership with pharma giant Merck to develop a therapy to treat glioblastoma, an especially deadly form of brain cancer. [Angela Shah, xconomy.com, Oct 6, 15]

DNAtrix (San Diego, CA and Houston, TX; no SBIR) that is modifying viruses to treat the most aggressive forms of cancer, said it has raised $20 million in a Series B round  [Alex Lash, xconomy.com, Oct 17, 14]

DNAtrix  (Houston, TX; no SBIR) biotech company that researches the use of viruses to target and destroy cancer cells, announced that it was awarded a $10.8 million grant to further its program for treating an aggressive form of brain cancer.  The Cancer Prevention and Research Institute of Texas (CPRIT) gave DNAtrix the grant to help the company usher its product, DNX-2401, a genetically modified adenovirus that attacks brain tumors, through the second stage of its first phase of development.  ...  In 2012,  DNAtrix merged with Vectorlogics (Birmingham, AL;  $2.8M SBIR)   [Josh Cain, Houston Business Journal, Feb 24, 14]

DNAtrix (Houston, TX; no SBIR)  Using a virus to attack cancer cells. ... conducting clinical trials on nine brain cancer patients at the University of Texas M.D. Anderson Cancer Center  ... received $500,000 from the state’s Emerging Technology Fund and is eligible to receive $500,000 more if it meets certain milestones. DFJ Mercury has invested about $480,000 in venture capital and the Marcus Foundation has given $2 million. ...  also received $4.5 million in federal grants for clinical production and testing. [Purva Patel, Houston Chronicle, Aug 28, 10]

DNV GL (Rochester, NY)

New York State Energy Research and Development Authority awarded $250K to  DNV GL (Rochester, NY; no SBIR) –  will develop a novel separator for lithium-ion batteries. ... to decrease the risk of fires due to Lithium-ion batteries, which – while rare – have occurred in the past. Ultralife (Newark, N.Y.) and Oak-Mitsui (Hoosick Falls, N.Y.) will participate in project reviews. The company will also investigate methods for automatically extinguishing a Lithium-ion fire should it occur. [NYSERDA, Oct 27, 14]

Dova Pharma (Durham, NC)

Dova Pharmaceuticals (Durham, NC; no SBIR) up 38% [Sep 30, 19] announced it has entered into merger with Swedish Orphan Biovitrum AB (Sobi) ... [for] total potential consideration of up to $915M ... to further accelerate growth in our haematology franchise. There is a large unmet medical need within thrombocytopenia and for us this is a great opportunity to be able to give patients access to new and improved treatments. [company press release, Sep 30, 19]

Dova Pharma up 22% [Aug 15, 17]

Dova Pharma up 20% [Aug 14, 17]

Dova Pharmaceuticals (Durham, NC; no SBIR) focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet need, announced the pricing of its [IPO] for total gross proceeds of  $75M  [company press release, Jun 28, 17]

Dova Pharmaceuticals (Durham, NC; no SBIR)  set terms of its [IPO] which the developer of drug candidates for diseases treated by specialist physicians expects to raise up to $69.1 million   [Tomi Kilgore, MarketWatch, Jun 20, 17]

Dova Pharmaceuticals (Durham, NC; no SBIR, founded 2016, four employees), focused on developing drugs to treat low blood platelet counts, is attempting to raise as much as $75 million through an IPO.  .... one promising drug candidate called avatrombopag, which it acquired from the Japanese pharmaceutical company Eisai in March 2016  [Zachery Eanes, Raleigh News & Observer, Jun 7, 17]

DoX Systems (Toledo, OH)

Rocket Ventures, a pre-seed, early-stage venture fund for technology-based [Ohio] companies, has awarded Ignite! grants to three Toledo firms - ADS Biotechnology, TechTol Imaging, and DoX Systems. These grants are given to help the companies develop and use technology to create new products or improve processes that have an impact on jobs and revenues in Northwest Ohio.   [Toledo Free Press, Jun 13, 08]  No SBIR.

Dragon Systems

Another buyout has much less basis for any paternity claim by SBIR. Dragon Systems a big research house (but still under 500 employees) in speech recongition was bought by a Belgian company Lernout & Hauspie for something like $600M. Dragon's SBIR experience is $400K ten years after its founding and in the middle of its growth to over 300 employees. Talk big and fast to convince anyone that $400K wasn't just another nickel in the piggy bank. Inknowvation, a persistent SBIR advocate, has tried to make the case by crediting a 1993 DARPA $250K Phase 2 with the key that opened the door. It sounds more taking credit for United Airlines success by buying one round-the-world ticket. Outside finance came from Seagate Technology 1994-1997 in the form of a seeming 35% equity stake after which a planned 1999 $100M IPO busted when earnings started to falter.Ah well, if you are an SBIR advocate justifying SBIR's economics, you need all the imagination you can muster for every success no matter how small.

Dragoon ITCN (Centerville, OH)

Dragoon ITCN (Centerville, OH; no SBIR, 13 employees, founded early 1990s) landed a $1.4 million [AF SBIR] contract ...  to upgrade a cable networks tester. ... Developed by the company years ago, Dragoon ITCN will work to add extra capabilities to the tester under the new contract   [Joe Cogliano, Dayton Business Journal, Nov 24, 14]   Downstream economic impact?  Where's the innovation that would open any new market?  What would have happened if the AF had opened the product improvement to open competition?  Who knows? This way the AF can use SBIR for ordinary product improvement that would probably fail any test of competitive innovation. The AF shows no sign of considering economic impact in awarding its SBIRs. The company's proximity to the AF flagpole also gave it some advantage in the occasions to schmooze AF officials and engineers. The Ohio Congresscritter for the district will surely rejoice in public.

Drilling Info (Austin, TX)

Drilling Info (Austin, TX; no SBIR) that provides data and intelligence to the oil and gas industry, has landed a $165 million equity investment that will help continue Drilling Info's swift growth, company officials said [Barry Harrell, Austin American Statesman, Mar 5, 12] 

DrillMap (Austin,TX)

DrillMap (Austin, TX;  SBIR) cleantech startup, said today it has raised $6.5 million in [Round A] venture capital.   [Angela Shah, xconomy.com, Aug 8, 13]

Dronewerx (Elyria, OH)

Dronewerx (Elyria, OH; no SBIR) has designed a new drone with shielded rotors that it hopes will make flying safer.  
....  an unmanned systems company has developed a multi-rotor drone, the DWX PG-Y6 Guardian — a craft with six motors and a prop guard that protects the aircraft rotors. ...  Multicopters are an especially popular form of UAS, common with hobbyists for their inexpensive price thanks to models like the DJI Phantom quadcopter   [Tristan Navera, Dayton Business Journal, Sep 8, 14]

DropWise (Cambridge, MA)

The [water-repellent] coating improves the efficiency of a key part of a power plant, the steam condenser.  ... is being commercialized by a startup called DropWise  (Cambridge, MA; no SBIR).   ...  To get the right thickness, MIT researchers invented a new process that involves flowing two gases past heated filaments. The gases react and form a polymer coating that is “just thin enough to still be much more efficient, but thick enough to be durable,” Boreyko [Virginia Tech professor and expert on heat transfer] says.  So far the coating technology has been tested only in the lab.   [Rachel Becker, technologyreview.com, Nov 20, 14]

DR Technologies (San Diego, CA)

DR Technologies (San Diego; $4M SBIR) has raised $4.5 million from private equity firm Nogales Investors of Los Angeles. The company makes composites for commercial, military, and scientific satellites and other space systems.  .... customers include Lockheed Martin Space Systems, Boeing, and Orbital Sciences. Nogales acquired a controlling stake in the company in 2009. [Mike Freeman, signonsandiego,com, Jun 10, 10]

DrugCendR(La Jolla, CA)

DrugCendR (La Jolla, CA; no SBIR) developing tumor-penetrating peptides that enhance delivery of anticancer drugs announced it has entered into a collaboration with Xiamen Tobefar Technology Co. Ltd  (China), partially owned by Peking University and Beijing Institute of Collaborative Innovation (BICI). [company press release, May 3, 17]

DSM (Exton, PA)

BiO2 Medical (San Antonio, TX; no SBIR, founded 2010) will use biosciences firm DSM’s (Exton, PA; no SBIR) lubricous coating on the Angel Catheter, its flagship product.  Placed at a patient’s bedside, the Angel is designed to protect intensive care patients from pulmonary embolism, or the blockage of an artery by a blood clot.  [Sanford Nowlin, San Antonio Business Journal, Nov 12, 13]

DT Solar

Last year, [Ted] Turner invested several million dollars in DT Solar (no SBIR), a New Jersey company .... He also created a holding company, Turner Renewable Energy, and said that he's looking to expand his holdings. ...According the Solar Energy Industries Association, the photovoltaic industry grew by nearly 80% last year, and the solar water heating business more than doubled. [Austin American Statesman, Sep 26]

DuBay Ingredients (Stratford, WI)

Two Wisconsin companies raised nearly $4.5 million of angel funding in the third quarter, according to the Wisconsin Angel Network. span style="font-weight: bold;">DuBay Ingredients (Stratford, WI; no SBIR) with a technology for producing ethanol from whey, raised $4.25 million from LA Investment Capital. The other company is span style="font-weight: bold;"> eContractorBids.com, Onalaska, which provides customers with competitive pricing from contractors and other building industry professionals.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 30, 09]

Dune Medical Devices (Atlanta, GA)

The scientists, leaders and investors of Dune Medical Devices (Atlanta, GA; no SBIR, founded 2002 ) [are] working towards eradicating the need for more than one operation to remove cancer from the body—a feat more than 20 companies have been unable to accomplish in the past two decades. The startup, which was founded in Israel in 2004 and later moved its operations to Atlanta, was founded by Dan Hashimshony, who discovered how to differentiate healthy tissue from cancerous tissue using physics and an algorithm. Using the algorithm, Hashimshony developed a pen-like probe that could determine if tissue was cancerous during surgery. [Madison Hogan, AtlInno, Jul 17, 19] total funding $50M [crunchbase.com]

duPont Aerospace (LaJolla, CA)

executives at duPont Aerospace (LaJolla, CA; one SBIR) continue to declare the discontinued experimental military plane – and, more specifically, its engines – theirs. ... refuses to turn over two costly engines nearly a year after NASA demanded their return. The engines were purchased with a 2002 government grant to the company, and are valued together at $1.5 million.  The parties appear poised to go to court to settle the issue. ... the congressman continued to push earmarked funding for nearly 20 years, finally totaling $63 million in 2007, the aircraft never passed a major technical review.   [San Diego Union Tribune, Nov 4]

Dura Biotech (Mansfield, CT)

Dura Biotech (Mansfield, CT; no SBIR), a startup, is expecting a $400,368 loan that Connecticut Inovations could choose to convert into an equity stake.... to work on early research for an aortic valve concept, and to fund an animal study of the valve, which is designed to be compressible to a smaller diameter as it is threaded through the body to reach the heart.     [Mara Lee, Hartford Courant, Aug 6, 14]

Durata Therapeutics (Morristown, NJ)

Durata Therapeutics  (Morristown, NJ; no SBIR) wants to raise $81 million [in an IPO]. The company, which has never been profitable, hasn't yet received approval for any of its drugs. Early-stage drug developers can have a difficult time pricing and trading even in perfect market conditions, although the last one that came public, Tesaro (no SBIR), priced within its expected range and traded up slightly during its debut last month.  [Lynn Cowan, Wall Street Journal, Jul 16, 12]

Durin Technologies (New Brunswick, NJ)

Durin Technologies (New Brunswick, NJ; no SBIR) has landed a $351,200 grant from the Michael J. Fox Foundation to expand the development of the company’s experimental blood test that can detect the presence of Parkinson’s disease earlier than the clinical observation of symptoms.  [John George, Philadephia Business Journal, Aug 29, 13]

DVS Sciences (Sunnyvale, CA)

Fluidigm (South San Francisco, CA: $1.1M SBIR) will buy DVS Sciences (Sunnyvale, CA; no SBIR)  in a cash and stock deal worth about $207.5 million. ...makes similar laboratory research equipment that Fluidigm said is "directly in-line with our strategy."  [Steven E.F. Brown, San Francisco Business Times, Jan 29, 14] 

DxUpClose (Frisco, TX)

Telemedicine Up Close (Frisco, TX; no SBIR) which operates as DxUpClose, was awarded $280,000 [from Texas Emerging Technology Fund] of up to $1.5 million for the commercialization of a diagnostic kit designed to identify bacterial infections and determine antibiotic treatment, Gov. Rick Perry’s office announced [Christopher Calnan Austin Business Journal, Jul 25, 13]

Dyadic International (Jupiter, FL)

Dyadic International  (Jupiter, FL; no SBIR) announced that it has entered into a definitive agreement to sell substantially all the assets of its Industrial Technology business to DuPont’s Industrial Biosciences business for $75 million in cash ....  Dyadic intends to focus exclusively on its biopharmaceutical business.  ...  intends to use a minimum of $15 million of the transaction proceeds to initiate a  stock repurchase program. [company press release, Nov 10,15]

Dyax

Dyax up 12% [Dec 3, 15]

Dyax (Cambridge, MA; $300K SBIR in 1999) up 28%, [Nov 2, 15]   Shire Plc (Ireland) has agreed to buy U.S. rare disease specialist Dyax for about $5.9 billion - and potentially up to $6.5 billion  ...  amid a record wave of deal-making in the broader healthcare sector so far this year, which amounted to $477 billion as of last week, according to Thomson Reuters data.    [Ben Hirschler, Reuters, Nov 2, 15]

Dyax up 19% [Oct 15,15]

Dyax up 54% [Apr 1,15] after the biopharmaceutical company reported favorable safety and efficacy results from an early-stage study of its treatment for hereditary angioedema attacks, which causes severe and painful swelling.  Dyax said the drug candidate, DX-2930, also received fast-track designation from the  [FDA]  [Josh Beckerman, Dow Jones Newswire,  Apr 1, 15]

In about two months, Dyax will report trial results on an injectable drug that could enable patients with a rare swelling disease called hereditary angioedema to live without fear of attacks.  [Don Seiffert, Boston Business Journal, Feb 12, 15]

Dyax down 10% [Dec 23, 14]

Dyax up 11% [Jul 30, 14]

Dyax up 13% [Jun 27, 14]

Dyax up 27% [May 27, 14]

Dyax down 10% [Apr 11, 14]

Dyax  down 10% [Apr 10, 14]

Dyax up 11% [Sep 26, 13]

Dyax said it has priced a registered direct offering for gross proceeds of approximately $30 million. ....  intends to use the net proceeds from this offering to fund research and development activities, including the development of DX-2930, a drug candidate for the treatment of hereditary angioedema, or HAE, and for general corporate purposes. [Boston Globe, May 13, 13]

Dyax  down 35% [Apr 26, 13]

Dyax up 20% [Mar 5, 13]

Dyax is partnering with CVie Therapeutics as part of plan to make Dyax’s hereditary angioedema drug available in China, Hong Kong, and Macau. The drug, Kalbitor, is currently marketed in United States for the treatment of acute attacks of hereditary angioedema  [Chris Reidy, Boston Globe, Feb 7, 13]

Dyax said it is partnering with a Colombian company that will develop and commercialize its hereditary angiodema treatment in such Latin American countries as Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The strategic partnership is with Novellus Biopharma AG of Bogota. Hereditary angioedema, or HAE, is a rare acute inflammatory condition characterized by episodes of severe, often painful swelling affecting the extremities, gastrointestinal tract, genitalia, and larynx. [Chris Reidy, Boston Globe, Jan 31, 13]

Dyax said it signed a deal with CMIC Co. to develop and sell the genetic disorder drug DX-88 in Japan.  ... Dyax will receive $4 million upfront and $102 million in future development and sales milestones for DX-88 in hereditary angioedema and other angioedema uses. [Boston Globe, Sep 30, 10]

Dyax said that it has launched a newly enhanced product website, that features the company's financial assistance program. KALBITOR is approved for the treatment of acute attacks of hereditary angioedema, or HAE, in patients 16 years of age and older. [Boston Globe, Jul 19, 10]

Dyax has partnered with Sigma-Tau SpA subsidiary Defiante Farmaceutica S.A. of Portugal on the development and commercialization of DX-88, an under-the-skin treatment for hereditary angioedema (HAE), in Europe, North Africa, Middle East and Russia. The deal will bring a total of $5 million to Dyax in upfront payments, with the potential to earn more than $100 million in milestone payments.  [Mass High Tech, Jun 21, 10]

Dyax stands to receive up to $12 million after selling certain rights to royalties to an investment fund [Mass High Tech, Apr 20, 10]

Cubist Pharmaceuticals announced that it will no longer develop its drug ecallantide, a potential therapy to control bleeding in high-risk cardiac surgery patients. ...  will end a licensing agreement with Dyax  which discovered ecallantide and licensed it to Cubist.  [Mass High Tech, Apr 2, 10]

Dyax announced a public stock offering. ..  for net proceeds of just about $3.4 million. [Mass High Tech, Mar 25, 10]

Dyaxsaid that KALBITOR, its treatment for acute attacks of hereditary angioedema in patients 16 and older, is now commercially available in the United States. [Boston Globe, Feb 2, 10]

Dyax jumped 21% [Dec 2, 09] after the FDA approved its ecallantide drug to treat acute attacks of rare swelling disorder known as hereditary angioedema in patients 16 years old and up. [Wall Street Journal, Dec 3]

Dyax said that it received a $1.5 million payment as Eli Lilly & Co. moved a potential leukemia treatment into early-stage clinical trials.  ... reported $43.4 million in revenue in 2008 [Boston Globe, Aug 26, 09]

Dyax says it is raising $15 million through a follow-on offering of 7.4 million shares of its common stock at a price of $2.02 per share.  ... development and commercialization of DX-88, the company’s treatment for the rare and often fatal condition hereditary angioedema [Mass High Tech, Jun 25, 09]

The FDA wants more information about Dyax's drug candidate DX-88 but won't require the company to conduct more tests, Dyax said late yesterday.  ... Shares fell 13% in aftermarket electronic trading [Boston Globe, Mar 27, 09]

Dyax and Fovea Pharmaceuticals SA said that they have entered into an exclusive license agreement for the development and commercialization of a Dyax drug candidate for the treatment of retinal diseases. [Boston Globe, Feb 9, 09]

Dyax said  that it has entered into a committed equity financing facility under which it may sell up to $50 million of its common stock to Azimuth Opportunity Ltd. over an 18-month period.  [Boston Globe, Oct 30,08]

Dyax  jumped 15% after the company reported positive results from a second late-stage study of its treatment for hereditary angioedema, a rare blood disorder. Dyax plans to apply for regulatory approval in the fourth quarter, which, if granted, would result in a mid-2009 launch.  [Wall Street Journal, Aug 19, 08]

Dyax said it is negotiating with an Italian pharmaceutical company over the European licensing of one of its drug candidates. [Boston Globe, Jul 15, 08]

Euro Too Dear. Dyax has begun talks about closing the research facility of its Belgian subsidiary in Liege, Belgium, officials report. ... enable Dyax to consolidate its discovery and preclinical programs at its headquarters in Cambridge, company officials said. The weakening U.S. dollar has contributed to a rise in operating costs in Europe.  [Mass High Tech, Apr 28]

Dyax entered into a license agreement with Paris-based sanofi-aventis that gives an exclusive worldwide license to the French pharmaceutical company for the tumor-fighting monoclonal antibody DX-2240  [Mass High Tech, Feb 12,08]

Dyax filed to raise up to $100M. [Dec 26, 07]

Dyax and German company MorphoSys AG announced the signing of a licensing agreement covering a broad patent portfolio relating to antibodies and protein. The agreement grants MorphoSys a fully paid up license to a variety of phage display-related patents from Dyax as well as other patents. [Chris Reidy, Boston Globe, Nov 20]

Dyax signed a third extension of the antibody library collaboration with New York-based ImClone Systems Inc. for the discovery of therapeutic antibodies, officials report. [Mass High Tech, Nov 8]

Dyax (Cambridge, MA: 3 Phase 1 SBIRs) signed a deal to discover therapeutic antibodies for a German pharmaceutical company. [Mass High Tech, Sep 6]

Dyax reports positive results from a Phase 3 clinical trail of the Cambridge firm's lead drug for the treatment of hereditary angioedema (HAE). [Mass High Tech, Apr 13]

Dyax (Cambridge MA) granted a non-exclusive license to its antibody phage display libraries to ZymoGenetics Inc. for the discovery of therapeutic antibodies. ...  The pact adds to Dyax's more than 75 revenue-generating licensing agreements for therapeutic discovery. [Mass High Tech, Oct 31]  Three Phase 1 SBIRs.

DynaBil Industries(Greene County, NY

DynaBil Industries (Greene County, NY; no SBIR)  plans to expand its business, investing almost $10M ...  will increase the size of the aeronautics parts manufacturer by well over 50%   ... manufactures precision aircraft sheet metal parts and assemblies from titanium, stainless steel, aluminum and exotic metals ...  such parts as titanium door and window frames and parts for the 787's floor. ... employs 200 people ... still a tiny piece of the aviation industry, worth about $205B last year.  [Alan Wechsler, Albany Times-Union, Apr 13]

Dynasil (Watertown, MA)

Med-tech firm Xcede Technologies (sub of Dynasil (Watertown, MA), Rochester, MN; no SBIR) closed on nearly $3 million for development of a patch that stops bleeding and seals tissue. [Minneapolis/ St Paul Business Journal, Dec 1, 15] Mayo Clinic has a financial interest in the technology ....  Revenue Mayo receives is used to support the clinic's not-for-profit mission in clinical practice, education and research.   [Dynasil press release, 2013]

Dynasil(Watertown, MA; no SBIR) announced that its RMD Research subsidiary has been awarded contracts totaling $3.65 million from the Department of Homeland Security... will foster Dynasil’s continued research and development of gamma and neutron radiation detectors capable of identifying illicit nuclear materials. [company press release, Dec 8]

Dynavax Technologies (Berkeley,CA)

Dynavax Tech (Berkeley, CA; $6.3M SBIR) up 16% [May 19, 22]

Dynavax Technologies down 20% [Nov 5, 21] reported third quarter finncial results

Dynavax Tech down 19% [May 10, 21]

Dynavax Technologies (Berkeley, CA; $6.5M SBIR) down 18% [Apr, 20, 21]

Dynavax up 63% [Feb 1, 21] Clover Biopharmaceuticals (China), and Dynavax Technologies announced the plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021 [joint companies press release, Feb 1, 21]

Dynavax (Emeryville, CA; $6M SBIR) up 25% [Jan 25, 21] Medigen Vaccine Biologics (Taiwan), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and Dynavax Technologies, a biopharma focused on developing and commercializing vaccines, announced that the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901. [joint companies press release, Jan 25, 21]

Dynavax Technologies up 20% [Jul 17, 20]

Dynavax Tech up 29% [Jun 1, 20]

Dynavax Tech up 26% [May 29, 20]

Dynavax Tech (Berkeley, CA; $6.5M SBIR) up 34% [May 19, 20] in anticipation of the company's COVID-19 vaccine program update, which is scheduled for later today. One of the main reasons for all the excitement is that Dynavax has already announced that one or more of its collaboration partners should initiate an early stage COVID-19 vaccine trial by July. [Motley Fool, May 19, 20]

Dynavax (Emeryville, CA; $6.5M SBIR) focused on developing and commercializing novel vaccines, and Sinovac (China) a leading provider of biopharmaceutical products in China, announced that they have entered into a collaboration to develop a vaccine to prevent COVID-19. The collaboration will evaluate the combination of Sinovac’s chemically inactivated coronavirus vaccine candidate, with Dynavax’s advanced adjuvant, CpG 1018 ™. [Dynavax press release, Apr 16, 20]

Dynavax (Berkeley, CA; $6.5M SBIR) up 15% [Dec 9, 19]

Dynavax Tech (Berkeley, CA; $6.3M SBIR, founded 1996) is pulling out of immuno-oncology R&D, laying off 82 staff and parting company with its CEO. The actions will create a slimmed-down commercial-stage company focused on selling hepatitis B vaccine HEPLISAV-B. [Nick Paul Taylor, Fierce Biotech, May 24, 19] total funding $175M [crunchbase.com]

Dynavax Tech up 18% [May 9, 19]

Dynavax Tech down 14%  [May 17, 18]

Dynavax Tech up 17%  [May 10, 18]

Dynavax Tech up 11% [Aug 7, 17]

Dynavax Tech up 71% [Jul 31, 17]  after [FDA] advisory committee said the safety data for its hepatitis B vaccination supported its approval.  [Dow Jones Newswire, Jul 31, 17]

Dynavax Tech down 11% [Jul 27, 17]

Dynavax up 11% [Jul 24, 17]

Dynavax Tech up 10% [Jun 12,17]

Dynavax up 17% [Jun 5,17]

Dynavax Tech (Berkeley, CA; $3.5M SBIR) up 53% [Mar 1,17] top percentage gainer ...  announced that [FDA]accepted for review Dynavax's responses to the Complete Response Letter (CRL) issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B, the company's vaccine candidate for immunization against hepatitis B infection in adults 18 years of age and older.  [compant press release, Feb 28, 17]

Dynavax up 10% [Dec 5, 16]

Dynavax Tech up 16% [Nov 15, 16] announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for HEPLISAV-B(TM) [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for immunization of adults 18 years and older against hepatitis B infection.  [company press release]

[FDA] rejected Dynavax Technologies, down 65%, marketing application for its hepatitis B vaccine, Heplisav-B, for the second time in three years, sending the company's shares tumbling 71 percent in premarket trade. [Reuters, Nov 14, 16]

Dynavax Tech up 19% [Oct 3, 16]

Dynavax Tech (Berkeley, CA; $3.5M SBIR) down 32% [Sep 2, 16] FDA announced that it had cancelled Dynavax's November 16, 2016 meeting with the Vaccines and Related Biological Products Advisory Committee "to allow time for the FDA to review and resolve several outstanding issues" with Dynavax's Biologics License Application for HEPLISAV-B(TM). [company press release, Sep 2, 16]  lawyers pounced for securities violations.

Dynavax Tech (Berkeley, CA; $3.6M SBIR)  down  12% {Apr 27, 16]

Sarepta Thera  down 26% [Apr 26, 16]

Dynavax up 11% [Jan 22, 16]

Dynavax down 10% [Jan 8, 16]

Dynavax Tech (Berkeley, CA; $3.6M SBIR) up 11% [Mar 23,15]

Dynavax Tech (Berkeley CA; $2.6M SBIR) down 10% [Dec 15, 14]

Dynavax Technologies (Berkeley, CA; $3.5M SBIR) said partner GlaxoSmithKline dumped a failed lupus drug. ...  The drug, called DV-1179, is part of a family of compounds designed to inhibit proteins known as toll-like receptors. ...  Dynavax said Friday that DV-1179 could be used in "a range" of other diseases, possibly including autoimmune pancreatitis and nonalcoholic steatohepatitis.    [Ron Leuty, San Francisco Business Times, Dec 1, 14] 

Dynavax Technologies (Berkeley, CA; $3.6M SBIR) started its first human trial of a potential asthma treatment.  ..... will enroll up to 45 people in this Phase I trial of AZD1419, an inhaled TLR9 agonist. These pioneering patients will all be healthy, and they'll get either the drug in ascending doses or a placebo.   ... treatment is being developed together with AstraZeneca   [Stephen EF Brown, San Francisco Business Times, Oct 9, 13]

Dynavax Tech  down 47% [Nov 16, 12]  following an unfavorable [FDA]panel safety view of its experimental hepatitis-B vaccine, Hepislav.  [Motley Fool] 

Dynavax down 23% [May 9, 12]   priced a stock offering at a 17% discount to Tuesday's closing price [Marketwatch.com]

Dynavax Tech  up 11% [Feb 2, 12]

Dynavax Tech  up 10% [Dec 20, 10]

Dynavax Technologies (Berkeley, CA; $2.2M SBIR) will start a 2,000-patient trial of its investigational adult hepatitis B vaccine, aiming for data in the first half of 2011. .. has a Phase III trial under way in chronic kidney disease patients using the same vaccine [Ron Leuty, San Francisco Business Times, Feb 8, 10]

The Nasdaq warned Dynavax Technologies (Berkeley, CA; $400K SBIR) it doesn’t meet a minimum shareholders’ equity rule for listing on the exchange.  [San Francisco Business Times, Nov 16, 08]

Dynavax down 59% after the FDA put a clinical hold on a late-stage trial for its Hepatitis B vaccine Heplisav. Dynavax and co-developer Merck said that one patient in a study outside of the U.S. was diagnosed with an uncommon disease causing blood vessel inflammation. All patients in that study have completed dosing with the vaccine. [theStreet.com, Mar 18,08]

Dynavax down 12% [Mar 17, 08]

Dynavax Technologies  up 12% [Feb 25, 08]

Merck has agreed to pay biotechnology company Dynavax Technologies (Berkeley, CA; two SBIRs)  up to $136M for the rights to co-develop and eventually sell Dynavax's experimental hepatitis B vaccine, [San Jose Mercury News, Nov 1, 07]

Dynavax Technologies fell 30% on poor results in its a clinical trial of its ragweed-allergy treatment Tolamba.  Two Phase 1 SBIRs.

Do-It-All Flu Shot. On the hunt for a vaccine against bird flu, biotech companies are coming up with leads on something even better: a universal vaccine that works against all kinds of flu. ... Dynavax Technologies in Berkeley believe they have found a possible solution. They have developed a vaccine that targets two other common flu proteins, the nucleoprotein and matrix protein, which tend to remain stable. [>Steve Johnson, San Jose Mercury News, Oct 30]  At least two Phase 1 SBIRs

Dynetics (Huntsville, AL and Arlington, VA)

Dynetics (Huntsville, AL; $5M SBIR), a Leidos company, has received a potential $124.7 million contract from the U.S. Army to provide cyber electromagnetic activities support for the service branch’s missile and space program executive office. [Jane Edwards, govconwire.com, September 13, 2023]

A Leidos Dynetics (Huntsville, AL ; $4.6M SBIR) subsidiary has received a potential four-year, $428.3 million contract modification from the U.S. Army to build prototypes of the Common-Hypersonic Glide Body system. [govconwire, Jul 25, 2023]

Leidos' Dynetics [Huntsville, AL; $5M SBIR) subsidiary has won a $478.6 million contract from the U.S. Army to develop a thermal protection system intended to protect surface-to-surface hypersonic missiles from intense heat during flight. Dynetics will build the Hypersonic Thermal Protection System prototype and help the military branch conduct materials research, inspection and acceptance efforts under the cost-plus-fixed-fee contract, the Department of Defense said [Angeline Leishman, govconwire, Nov 22, 21]

Dynetics (lots of SBIR), a wholly owned subsidiary of Leidos , has secured a potential $90 million contract to build a laser-based technology to measure the temperature, pressure, carbon dioxide and oxygen within the Orion spacecraft during NASA's planned human missions to the moon. [govconwire.com, Jun 1, 21]

Leidos's  Dynetics (many SBIRs near the Huntsville AL flagpole) subsidiary has secured a potential 10-year, $356M contract to produce and maintain a suite of foreign radar simulators for use by the U.S. Air Force and the Department of Defense in enterprise-wide test efforts [Mary-Louise Hoffman, govconwire.com, Jun 22, 20]

Leidos agreed to acquire technology services contractor Dynetics (Huntsville AL; lots of SBIR) for $1.65B cash to further build up its position in the intelligence, civil and defense markets. [Jane Edwards, GovConWire.com, Dec 18, 19]

Dynetics (Arlington, VA and Huntsville, AL; at least 30 SBIRs) has secured a potential 10-year, $737.9M contract for support services to a facility where the Defense Intelligence Agency assesses data on foreign weapons systems. DoD noted the contract includes a five-year option period that could extend the performance of work through Oct. 31, 2029 [Matthew Nelson, govconwire.com, Nov 4, 19]

A team led by Dynetics (Arlington, VA and Huntsville, AL; at least 30 SBIRs) technical solutions business will develop prototypes of the Common-Hypersonic Glide Body system under a potential three-year, $351.6M other transaction agreement with the U.S. Army. Dynetics said it will work with Lockheed Martin, Raytheon, and General Atomics’ electromagnetic systems business on the C-HGB prototype development project. [Jane Edwards, GovConWire, Aug 30, 19]

Dynetics was one of eleven companies picked by NASA to produce prototypes of a human [lunar] landing platform with descent, ascent, transfer and refueling elements and shoulder at least 20 percent of the total development cost under the Next Space Technologies for Exploration Partnerships Appendix E contracts. [Jane Edwards, GovConWire, May 17, 19]

The U.S. Army selected Dynetics (at least 30 SBIRs) to be the prime contractor on a potential $130M contract to build and demonstrate a 100-kilowatt-class laser weapons system. Dynetics said Wednesday its partners for the High Energy Laser Tactical Vehicle Demonstrator program are Lockheed Martin, Rolls-Royce and MZA Associates. [Mary-Louise Hoffman, GovConWire, May 16, 19]

[John] Ismay writes [New York Times] that "In June 2018, [manufacturer] Dynetics {at least 30 SBIRs) received a $470 million 'indefinite quantity' contract to supply Special Operations Command with GBU-69s." A spokeswoman told the Times USSOCOM has ordered more than 2,000 of the GBU-69s already. Read on, here . [defenseone.com, Mar 28, 19]

DARPA has awarded Exquadrum (Adelanto, CA; 48 SBIRs) and Dynetics (Huntsville, AL; 32 SBIRs) a contract to develop technology for hypersonic weapons. Called the Operational Fires (OpFires) Propulsion System program, "the program aims to develop and demonstrate a novel ground-launched system for hypersonic boost glide weapons to penetrate modern enemy air defenses and rapidly and precisely engage critical time sensitive targets," the companies said in a joint statement. [DefenseOne, Jan 17, 19]

Future Army contracts. The Army revealed a new roster of industry partners under a potential $37.4B contract that covers knowledge-based professional engineering support services to command, control, communications, computers, intelligence, surveillance and reconnaissance programs. SBIR companies: Artel (now big, $300K); Dynetics (now big, 31 awards); Macaulay-Brown (now big, 23 awards); NetCentric (now big, $900K); Scientific Research (Now big, $16M); Array Information Technology (one SBIR); Bennett Aerospace (21 SBIR awards); Envistacom (one SBIR); Fibertek (127 SBIRs); Future Technologies ($1M); Fulcrum ($1.2M); LinQuest ($1M); Manufacturing Techniques (One SBIR); Navmar Applied Sciences (68 awards); Peerless Technologies ($2.6M); Research Innovations (one SBIR); Sonalysts (128 awards); SURVICE Engineering (50 awards); Truestone (one SBIR).[GovConWire, Oct 19, 18]

Dynetics (Arlington, VA and Huntsville, AL, $6M SBIR, founded 1974) landed a potential $470 million sole-source contract to manufacture GBU-69/B Small Glide Munitions for the U.S. Special Operations Command  [Nichols Martin, GovConWire, Jun 11, 18]

DARPA's "Gremlin" swarm drone attack and recovery program is picking up speed with a late-April "21-month, $38.6 million contract to Dynetics (Huntsville, AL; $6M SBIR)" the Washington Post reported this weekend. Dynetics will be working with " Kratos (San Diego, CA; no SBIR), a venture-funded tech company that specializes in cheap drones used for target practice." [DefOne, May 7, 18]

Dynogen Pharmaceuticals

At least five Massachusetts biotechs — Dynogen Pharmaceuticals Inc., Epix Pharmaceuticals, Oscient Pharmaceuticals, Biopure Corp. and span style="font-weight: bold;">Altus — have more or less ceased operations since the stock market meltdown in September 2008.  [Julie Donnelly, Mass High Tech, Mar 5, 10]

Dynogen Pharmaceuticals (Waltham, MA; no SBIR) filed for Chapter 7 bankruptcy protection this week, meaning the company will likely be liquidated.... burned through at least $67 million in venture capital and other funding... trying to develop drugs for irritable bowel syndrome, overactive bladder disorder, and nocturnal gastroesophageal reflux disease (often associated with heartburn).  [Boston Globe, Feb 24, 09]

Apex Bioventures Acquisition Corp. said it agreed to acquire for $98M in stock span style="font-weight: bold;">Dynogen Pharmaceuticals (Waltham, MA; no SBIR) focused on gastrointestinal and genitourinary disorders. [Boston Globe, Feb 7, 08]

E25 Bio (Cmbridge, MA)

E25Bio (Cambridge,MA; one SBIR) rapid diagnostic innovators, announces award funding of $4.14M from the Bill & Melinda Gates Foundation and $1.68M [NIH SBIR]. [company press release, Aug 13, 20]

E3 Clean (Athens, OH)

Start-up Silicon Valley.   SVForum names [as Most Likely to Succeed] Algorithms.io, Bugcrowd, FLASHiZ (Luxembourg), WHILL (from Japan), E3 Clean (Athens, OH), OnFarm (Fresno, CA) as the winners of honor that draws attention of venture capitalists and angel investors.  [San Jose Mercury News, Jun 5, 13]  None has SBIR.

Eagle Optoelectronics (Boulder, CO)

A Business Week story says Eagle Optoelectronics Inc. (Boulder, CO) is in the van on WDM plug-in optical cards. Eagle got its only Phase 2 SBIR from BMDO in 1995 for a new type of an "intelligent" DWDM transceiver able to tolerate millisec-scale time-varying wavelengths.

Earl Energy (Virginia Beach, VA)

Earl Energy  (Virginia Beach, VA; no SBIR, 10 employees) said it has won a $1.2 million U.S. Army a multi-year contract to develop large power converters for the military. ...  developing a Silicon Carbide power converter that the company says is 80 percent lighter and 350 percent more powerful than existing converters. ... has developed a laboratory model and is now working on a prototype for the Army. [Lauren Ohnesorge, Raleigh News & Observer, Sep 6, 13]  owned and led by veterans [company website]

EarLens (Redwood City, CA)

Lightstone Ventures closed its first fund at $172 million, aimed at biotech and medical device companies.  ....  will make about five investments per year, Carusi told Dow Jones, with three-quarters of the investments in early-stage biotech and medical device companies  ....   has invested in  hearing aid company EarLens (Redwood City, CA;  $900K SBIR)  as well as Catabasis Pharmaceuticals (Cambridge, MA; one SBIR), a clinical stage biotech company targeting cardiovascular, metabolic and inflammatory diseases, and FIRE1, a therapeutic device company in Ireland.  [Ron Leuty, San Francisco Business Times, May 1, 14]

Earth Networks (Germantown, MD)

Fifteen university research teams from Maryland will receive a total of $4.1 million to work with local companies to turn their research into products that could one day be sold on the commercial market.  .... MIPS will contribute $1.8 million and private companies will contribute $2.8 million. The companies:  A&G Pharmaceutical (Columbia, MD; no SBIR),  Rehabtics LLC (Baltimore, MD; no SBIR)  High Impact Environmental (Church Hill, MD; no SBIR),  Birich Technologies (Towson, MD; no SBIR), Earth Networks (Germantown, MD; no SBIR), Fiberight (Halethorpe, MD; no SBIR), CoolCAD Electronics (College Park,MD $1.6M SBIR), XChanger Companies (Annapolis, MD; no SBIR), Remedium Technologies (College Park, MD; no SBIR), Pothole Pros LLC (Waldorf, MD; no SBIR), Hoopers Island Oyster Aquaculture (Fishers Creek, MD; no SBIR),  Metompkin Seafood (Crisfield, MD; no SBIR) GreatGrow Maryland LLC (Rock Hall, MD; no  SBIR), vCalc (Hagerstown, MD;  SBIR), Shore Thing Shellfish (Tall Timbers, MD; no SBIR). ($114,094)  [Sarah Gantz,  Baltimore Business Journal, Feb 26, 14] 

Earthrise Nutritionals (Irvine,CA)

Sapphire Energy (San Diego, CA; $200K SBIR) startup developing algal biofuel, said it successfully modified certain cyanobacteria, also known as blue-green algae, to produce significantly higher yields of “green” crude oil. Sapphire said it also has tapped into the deep expertise in producing blue-green algae through a licensing agreement with Earthrise Nutritionals (Irvine, CA; no SBIR), which produces food colors and nutritional supplements from a type of blue-green algae known as Spirulina.  [Bruce Bigelow, xconomy.com, Mar 2, 12]

eASIC (Santa Clara, CA)

Custom chip designer eASIC (Santa Clara, CA; no SBIR, founded 1999) disclosed  that it plans to raise $75 million in an upcoming IPO. ... raised more than $139 million  [since founding]  [Cromwell Schubarth, Silicon Valley Business Journal, Feb 20, 15]

Eboo Pharmaceuticals (Durham, NC)

A 2-year-old pharmaceutical startup Eboo Pharmaceuticals (Durham, NC; no SBIR) specializing in Parkinson's disease treatment has won grant support up to $1.5 million from the high-profile Michael J. Fox Foundation for Parkinson's Research.  ....   "virtual" company with no employees, no office and a post office box address ..... expected to provide an efficacious and well-tolerated initial monotherapy without the debilitating side effects of current therapy.  [John Murawski, Raleigh News & Observer, Jun 20, 13]

EBR Systems (Sunnyvale, CA)

EBR Systems  (Sunnyvale, CA; no SBIR) developer of a wireless cardiac pacing system, raised $20 million in venture funding ... has raised $81 million to date. ...  eliminates the need for leads and lets the physician place the endocardial technology at the most optimal site (inside the left ventricle) where it can be most effective.     [Gina Hall, Silicon Valley Business Journal, Apr 8, 15]

Ebullient (Madison, WI)

Ebullient (Madison, WI; no SBIR) start-up that is developing a computer cooling technology, has raised $535,000 of a proposed $646,000 funding round, another SEC filing said. Ebullient's technology, which uses liquid rather than air to cool computers, was developed by Timothy Shedd, a mechanical engineering professor at the University of Wisconsin-Madison. [Milwaukee Journal Sentinel, Jan 19, 15]   dramatically decreases the iconic noise for which data centers are known ... can cool any data center computer load on the hottest day ever recorded in Death Valley without a compressor, air conditioner or cooling tower ... many state incentive programs reward Ebullient system installations and can subsidize your purchase   [Company website]

Eccrine Systems (Cincinnati , OH)

Sweat technology startup Eccrine Systems (Cincinnati , OH; no prior SBIR, founded 2013)  awarded a $750,000 [USAF] SBIR Phase II contract focused on real-time measurement of specific biomarkers in human sweat as an index of cognitive performance. [company press release, Feb 1, 18]

Echelon

Echelon (Santa Clara, CA; one SBIR, 74 employees) up 98% [Jun 29, 18] Adesto Technologies (Sunnyvale, CA; $800K SBIR), a leading provider of innovative application-specific semiconductors for the IoT era, and Echelon Corporation announced a definitive agreement under which Adesto will acquire Echelon for [a total equity value of approximately $45 million] Echelon is a pioneer in the development of open-standard networking platforms for connecting, monitoring and controlling devices in commercial and industrial applications. [Echelon press release, Jun 29, 18]

Echelon up 11% [Oct 13, 17]

Echelon down 10% [May 6,16]

Echelon down 16% [Feb 7,14] 

Echelon up 17% [Jan 31,14] 

Echelon up 19% [Jan 28,14]

Echelon up 10% [Sep21, 12]

Echelon down 11%[May7,10]

Echelon up 10%[Apr21,10]

Echelon up 11%[Sep28,09]

Echelon up 21%[Aug28,09]

Echelon up 21%[Aug10,09]

Echelon down 10%[Apr7,09]

Echelon up 13% [Mar 10, 09]

Echelon up 11% [Feb 13, 09]

Echelon   up 10% [Feb 6, 09]

Echelon down 11% [Jan 20, 09]

Echelon up 13% [Dec 17, 08]

Echeoln up 11% [Dec 16, 08]

Echelon up 11% [Dec 12, 08]

Echelon up 15% [Dec 8, 08]

Echelon  down 16% [Dec 1, 08]  On a stock bloodbath day

Echelon up 13% [Nov 26, 08]

Echelon up 11% [Nov 24, 08]

Echelon down 10% [Nov 14, 08]

Echelon down 10% [Nov 6, 08]

Echelon down 24% [Sep 29, 08]

Echelon down 11% [Sep 26, 08]

Echelon up 15% [Sep 18, 08]

Echelon up 10% [Sep 16, 08]

Echelon up 11% [Aug 13, 08]

Echelon down 14% [Jul 30, 08]

Echelon up 13% [Jul 14, 08] on news of a Danish deal to service 390,000 homes.

Echelon up 11% [May 27, 08]

Echelon up 12% [May 15, 08]

Echelon down 11% [Apr 29,08] on accounting problems.

Echelon down 10% [Mar 27, 08]

Echelon up 12% [Mar 5, 08]

Echelon up 18% [Feb 7, 08] on good earnings.

Echelon down 10%. [Dec 31, 07]

Echodyne (Bellevue, WA)

radar company Echodyne (Kirkland, WA; one SBIR) raised $135 million. Bill Gates and Baillie Gifford led the funding. [Rick Morgan, Seattle Inno, June 13, 2022]

Tom Driscoll's Echodyne (Bellevue, WA; no SBIR) may be the only [company] whose quadcopter packs the kind of sophisticated radar used on fighter jets ...  Driscoll’s drone carries an electronically scanning radar instrument that doesn’t have a conventional phase shifter. The outgoing radio waves are steered with a much simpler device, built using techniques borrowed from a relatively new area of research on what are known as metamaterials.  ... Metamaterials are made from repeating structures that are smaller than the wavelength of the electromagnetic radiation being manipulated.  ...  hopes to mass produce compact radar systems that cost only hundreds or thousands of dollars. ...  also received investment funding from Microsoft cofounder Bill Gates  [Tom Simonite, technologyreview.com, April 6, 2015]

Echodyne (Bellevue, WA;  Bill Gates is better than SBIR), the secretive  company that spun off of Intellectual Ventures, said it's raised $15 million in an initial funding round led by Bill Gates ...  noting that it "will bring to market radar products based on metamaterials technology invented by Intellectual Ventures in collaboration with Duke University and the University of California at San Diego." ... Metamaterials, Echodyne said, are "artificially structured materials used to control and manipulate a range of physical phenomena, including electromagnetic radiation."   [Ben Miller, Puget Sound Business Journal, Dec 19, 14]

Echogen Power Systems (Akron, OH)

The Department of Energy will award $128M to support 75 research projects that seek to advance the development of solar technologies. Most money went to academic and large businessses. Several awards went to former SBIR winners: Energy Materials (Norcross GA one SBIR) won a $4M Solar project award to create new methods to deposit layers of material to make the cell, develop a high-speed process ; Leading Edge Crystal Technologies (Gloucester, MA; one SBIR) won $2.5M to develop a floating-silicon method for producing high-quality single crystalline wafers ; Sunvapor (Livermore, CA ; one SBIR) won $2.5M to show how using enormous tanks that normally store liquefied petroleum gas can be used to accumulate and store solar-generated steam ; Brayton Energy (Hampton,NH; $3M SBIR) won $700K to partner w Oak Ridge Lab to examine examine creep behavior—the tendency to deform under mechanical stress—in thin-sheet nickel alloys; Ceramic Tubular Products (Lynchburg, VA; $3.2M SBIR) won $1.9M to develop silicon carbide composite receiver tubes for molten chloride salt and liquid sodium receivers; Echogen Power Systems, (Akron, OH; $300K SBIR) won $4.4M to develop a large-scale, low-cost, single-shaft compressor for supercritical carbon dioxide (sCO2) power cycles; Osazda Energy (Albuquerque, NM; one SBIR) won $1M to develop a cost-effective metal paste that strengthens the metal connections in solar cells; Scion Plasma (East Lansing, MI; $200K SBIR) won $1M to develop a tool that rapidly deposits transparent conductive oxide onto heterojunction silicon with intrinsic thin layer (HIT) solar cells; Swift Coat (Peoria, AZ; one SBIR) won $1M to make and scale multilayer, anti-reflective and anti-soiling coatings for solar glass [Jane Edwards, govconwire, Nov 7, 19]

Echometrix (Madison,WI)

Six start-ups will be recognized for making strides to commercialization at a biotech industry summit in October. ... part of a one-day Biotechnology Vision Summit 2009 that is being run by BioForward, an organization that represents Wisconsin's biotech industry. AquaMost LLC (Madison, WI; one SBIR) , Echometrix  (Madison, WI; no SBIR), Flex Biomedical Inc(Madison, WI; one SBIR), Semba Biosciences (Madison, WI; no SBIR),  Invivosciences LLC (Wauwatosa, WI; no SBIR), and Rapid Diagnostek Inc  (Hudson, WI; no SBIR).  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 22, 09]

EchoPixel (Mountain View, CA)

Two Silicon Valley companies have developed a 3-D virtual reality kit that lets medical students and doctors practice surgeries and organ dissections without the messiness of working on real cadavers.  Three-dimensional holographic imaging display maker zSpace (Sunnyvale, CA; no SBIR) provides the hardware, including stereoscopic VR displays and transparent glasses. EchoPixel (Mountain View, CA; no SBIR) which makes medical imaging technology, provides the software. ... They plan to submit a proposal next week to [FDA] that, if approved, would allow them to start selling the kits for $75,000 — for use in clinical settings with real patient data.   [Jose Fermoso, Silicon Valley Business Journal, Dec  9, 14]

EcoPro Polymers (Corvallis, OR)

EcoPro Polymers (Corvallis, OR; no SBIR) startup is working on what could be the first non-toxic adhesive for the wood products industry.   Oregon BEST has invested $124,000 of early-stage funding to speed commercialization of the adhesive [the first to not contain urea-formaldehyde] which is collaborating with Oregon State University researchers on the product.  [Portland Business Journal, Dec 1, 15]

Echo Therapeutics (Franklin, MA)

Echo Therapeutics' (no SBIR) largest investor has agreed to invest another $4 million in the Philadelphia medical device company under a deal that will result in the departure of three Echo board members. ... attempting to commercialize a wireless and needle-free continuous glucose monitoring system. It suspended its product development, research, manufacturing and clinical programs and operations in late September to conserve its remaining cash.    [John George,Philadelphia  Business Journal, Dec 22, 14]

Platinum Management said this week it has informed the board of Echo Therapeutics (Philadelphia, PA; no SBIR) that it intends to seek the return of its $5 million investment .. developing a wireless and continuous glucose monitoring system for use initially with patients in critical-care settings ...  Platinum said when it made its investment, it was given assurances Echo would focus it efforts on the commercialization of its experimental products. Platinum arranged for Echo to work with, and potentially get additional funding support from, Medical Technologies Innovation Asia (MTIA) Ltd.  ....  The letter alleges the company’s board reneged on its obligations to Platinum, and has not spent its investment funds on “developing products that will raise the stock price and benefit all stockholders.”      [John George, Philadelphia Business Journal, Sep 18, 14]   

Capital demands its say.   Echo Therapeutics’s (Philadelphia, PA; no SBIR) largest shareholder sent a letter to the  company's stock holders urging them not to re-elect current director and interim-CEO Robert F. Doman to Echo’s board of directors.  ...  Platinum Management — which has invested $18.6 million in Echo — said it “can no longer sit idly by while stockholders continue to suffer under the direction of the current board.” Platinum Management, which owns about 20 percent of Echo’s common stock   .... is developing the Symphony CGM System, a wireless continuous glucose monitoring system for use initially in post-surgical patients at critical-care units in hospitals [John George, Philadelphia Business Journal, Apr 23, 14]  If you can't grow your own capital, you'll have to invite new owners with new opinions, or convince a gullible government to give you something for nothing. Fortunately, US politicians love to give something for nothing for non-economic reasons. And as you can inagine, there is a long queue at government's door.

Echo Therapeutics (no SBIR) said it has reduced its workforce by 33 percent, or about a dozen people. The move is part of a cost-reduction initiative designed to conserve cash while the company works toward getting its lead product approved in Europe and the United States. [John George, Philadephia Business Journal, Oct 3, 13]

Echo Therapeutics (Philadelphia, PA; no SBIR) raised $12.5 million in a public stock sale ... developing a non-invasive and wireless continuous glucose monitoring system called Symphony.  [John George, Philadelphia Business Journal,  Jun 19, 13] did a 1-for-10 reverse split of its common stock Jun 5

Echo Therapeutics (Franklin, MA: no SBIR), a medical technology company making a needle-free monitoring and drug delivery system, has taken in $5.5 million in a set of new financing deals  [Rodney Brown, Mass High Tech, Jan 6, 11]

Echo Therapeutics (Franklin, MA; one SBIR as span style="font-weight: bold;">Sontra Medical) got its wish, landing a $2 million equity financing round ... In June, Echo licensed its needleless glucose-monitoring technology to South Korea-based Handok Pharmaceuticals Co. Ltd. for $600,000 and royalties and other payments. [Mass High Tech, Jul 29, 09]

Sontra Medical (Franklin MA; one SBIR) a developer of transdermal treatments and diagnostics, reports it has officially changed its name to Echo Therapeutics[Mass High Tech, Oct 8, 07]

ECI Biotech (Worcester, MA)

The Massachusetts Life Sciences Center, a quasi-public agency, awarded $3.75 million in loans to five early-stage life sciences companies. AesRX (Newton, MA; no SBIR)  biopharmaceutical company focused on the development of sickle cell disease and other orphan drugs; MoMelan Technologies (MA; no SBIR) medical device company; Myomo (Cambridge,MA; one SBIR) focused on helping people move again after a neuro-muscular impairment; ECI Biotech (Worcester, MA $1.6M SBIR) developer and manufacturer of affordable diagnostic sensors that can be incorporated into any consumer product or medical device; and Grove Instruments (Worcester, MA; $400K SBIR)developing a painless, noninvasive technology that accurately measures blood sugar.  [Boston Globe, Mar 23, 11]

ECM Technologies ((Houston,TX)

ECM Technologies LLC (Houston, TX; no SBIR)  raised the first portion of a seed round to help develop the company as it moves closer to manufacturing [of]. ollagens for biomedical needs  ... was a part of the Texas Medical Center's first TMCx accelerator class.  [Joe Martin, Houston Business Journal. Apr 11, 16]

Ecocurrent

Thirteen NC companies will split $1 M from a new state fund intended to help businesses create environmentally friendly technologies. In the Triangle area: Ecocurrent of Raleigh received $100,000 to convert hog manure into electric power; Kyma Technologies of Raleigh received $60,000 to work with N.C. State University on a more efficient, cheaper electric switch.; 3F LLC of Raleigh received $100,000 to develop a natural fiber-reinforced concrete formula.; Piedmont Biofuels of Pittsboro received $75,000 to work on a reactor that more efficiently creates biodiesel.; Nextreme Thermal Solutions of Durham received $57,319 to manufacture a generator that converts waste heat into electricity.; Rain Water Solutions of Raleigh received $18,000 to develop a new rain barrel manufacturing process. [Raleigh News & Observer, Jul 1]

EcoPesticides (Albuquerque, NM)

EcoPesticides (Albuquerque, NM; no SBIR) closed out a $400,000 [Series A] round of funding. ...  a part of the New Mexico Angels' Startup Factory and is using technology developed at UNM. It makes microbial pesticides, which is a new class of pesticides that use microbes to target certain pests without harming water, plants or other animals. EcoPesticides developed a new capsule for the fragile microbes that shields them from the elements but not from the insects that eat them. ...  [CEO] Stewart said he expects to raise another $3 million to $5 million later to bring a product to market.   [Dan Mayfield, Albuquerque Business First, Jan 20, 15]

Ecovative Design (Green Island, NY)

Ecovative Design (Green Island, NY: $4.5M SBIR) raised $60M in Series D financing (Albany Business Review, Mar 30, 21]

Ecovative Design (Green Island, NY; $600K SBIR) awarded a contract valued at up to $9.1 million from the [DARPA] to develop next generation building materials: living materials that are more versatile, more efficient, and more cost effective in rapidly creating structures, by literally growing those structures in places where they are needed.  ...  founded on the fundamental breakthrough idea that the mycelium of a mushroom can work as “nature’s glue” to bind agriculture salvage and/or wood products together.  [company press release, Jun 28, 17]

Ecovocative (Green Island, NY; $600K SBIR, founded 2006) is ringing NASDAQ's closing bell Feb 12 with the head of SBA  [Chelsea Diana, Albany Business Review, Feb 12, 16]  in 2006 Eben and Gavin team up in a class called Inventor’s Studio at RPI to invent a new insulation material using agricultural waste and mycelium.  in 2007 Eben and Gavin graduate RPI and are convinced by their professor, Burt Swersey, to pursue the technology into a company.   ...  commercialized custom molded protective packaging called Mushroom® Packaging, an engineered wood alternative called Myco Board   [company website]

Ecovative Design  (Green Island, NY; $600K SBIR, founded 2007, 60 employees), the startup whose innovative mushroom technology is serving as packaging material for such big players as Dell Inc. and Steelcase Inc., has raised more than $14 million in private equity ... uses mushroom roots and vegetative waste to make a natural, biodegradable replacement for Styrofoam and other foams and plastics.  ....  plans to build its first out-of-state manufacturing plant in Cedar Rapids, Iowa to be closer to Sealed Air, an $8 billion company, [and the sole licensee of Ecovative's mushroom packaging. .... In 2011, the company received a multi-million-dollar investment from 3M, Rensselaer (Poly Inst) and the Dutch-based DOEN Foundation.  ....  won $100,000 through the Buckminster Fuller Institute in Oct 13.    [Pam Allen, Albany Business Review, Nov 7, 13]

Ecovative Design  (Green Island, NY;  $600K SBIR, 70 employees), was awarded $350,000 [from the state’s Energy Research and Development Authority] to improve the energy efficiency of the manufacturing processes used to produce its product, a packaging foam synthesized from farm by-products. .... has been making a natural alternative to standard packaging foam by bonding farm by-products through adhesives found in mushrooms.    [Troy Record, Feb 15, 13]

Edaptive Computing (Centerville, OH)

Edaptive Computing (Centerville, OH; $12.5M SBIR, founded 1997, 60 employees) won Air Force deal that could be worth as much as $20 million during the next five years. .... to help the Large Aircraft Infrared Countermeasures Program office improve its operations   [Joe Cogliano, Dayton Business Journal, Jul 29, 14] Thirteen years of software SBIR for a firm near the AF flagpole. 

Edaptive Computing (Centerville, OH; $13M SBIR, founded 1997) won a U.S. Air Force deal that could be worth as much as $4 million during the next few years.   ...  to support rapid technology transition  ....  may help the military predict how flying more missions would affect its overall supply chain performance and weapon system availability.   [Joe Cogliano,     Dayton Business Journal, Jun 27, 14] How nice and warm.

Eden Bioscience

Eden Bioscience (Woodinville, WA; one small SBIR years ago) which went public in 2000 and raised $133 million over the years, said it will delist and deregister its stock at the end of the month as it winds down the business.  [Seattle Times, Jun 19, 09]

After more than a year of limping along, Eden Bioscience (Woodinville, WA; one SBIR a decade ago) said that it will liquidate its assets.  [Seattle Times, Dec 6, 08] Eden Bioscience up 77% to $1.40 a share but down more than 99% from $400 in 2001 ...  sells harpin protein-based products to the home and garden markets in the United States. [Yahoo Finance]

Eden Bioscience  up 23% [Apr 18, 08]

Edgybees

The U.S. Air Force has tentatively selected over 500 companies for contracts worth $550M combined as part of an initiative launched with its AFWERX innovation arm and [SBIR]. The service said the AFVentures effort includes a strategic financing initiative where the firms will get a total of over $200M in government funding as well as $350M in private funds. [Brenda Marie Rivers, govconwire, Mar 16, 20]  almost half going to the following 21 companies: Aerial Applications, Analytical Space ($3M prior SBIR), Anduril (one prior SBIR) , Applied Minds ($8M prior SBIR), Elroy Air, Sentient ($3.2M prior SBIR) , Icon, Enview ($700K prior SBIR), Edgybees ($700K prior SBIR) , Falkonry (one prior SBIR), Swarm Technologies ($1M prior SBIR) , Orbital Insight (one prior SBIR), Orbital Sidekick ($800K prior SBIR), Virtualitics (one prior SBIR) , Wickr (one prior SBIR), Tectus Corp (one prior SBIR), Valulytics, Shift.org, Pison ($1M prior SBIR), Revacomm. One other company hasn’t been named yet. These “big bet” companies are slated to receive four-year, fixed-price contracts worth a combined $550+ million through AFVentures’ Strategic Financing (STRATFI) program. This amount includes $100+ million in SBIR funds, $100+ million in Air Force funding and $350+ million in private investment. Roper said he believes future rounds of funding will be bigger. [AF Press release , Mar 13, 20]

Edico Genome (San Diego,CA)

Illumina announced that it acquired Edico Genome (San Diego, CA; no SBIR, founded 2013), the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. [company press release, May 15, 18] the deal is reportedly worth $100 million [Chris Jennewein. timesofsandiego.com, May 16, 18]

Illumina announced that it acquired Edico Genome (San Diego, CA; no SBIR, founded 2013), the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. [Illumina press release, May 15, 18] for $100M ;total Edico funding $32M [crunchbase.com]

Edico Genome (San Diego, CA; SBIR), which makes a fast processing platform for next generation gene sequencing, said Tuesday that it has raised $22 million in a second round of venture capital fundingled by Dell Technologies Capital.  
Though it has been quietly investing in startups for a couple of years, Dell Technologies Capital revealed its $100 million start-up fund on Monday after previously operating in stealth mode. [Mike Freeman, San Diego Union Tribune, May 9, 17]

Edico Genome (San Diego, CA; no SBIR, 28 employees) a startup that makes a high-speed DNA sequence analyzer, said it has collaborated with Intel to help its Xeon chips analyze DNA sequence data. ... said it has been granted its first patent, for the technology in its Dragen bio-IT microprocessor ... Products from the Edico/Intel alliance should hit the market starting next year, said [CEO Pieter van Rooyen].    [Bradley Fikes, utsandiego.com, Apr 21, 15]

Edico Genome (La Jolla, CA; no SBIR, founded 2013) took first place [in The Scientist top ten innovation list] for its Dragen Bio-IT Processor. The add-on card accelerates the analysis of genomic data by a factor of 30, says Pieter van Rooyen, Edico's president and chief executive.  ....  Genome sequencers from Illumina took second and third place   [Bradley Fikes, utsandiego.com, Dec 1, 14]  Other winners: BioNano Genomics, RainDance Technologies  (Lexington, MA; $1.1M SBIR) , Leica Microsystems, Organovo  (San Diego, CA; $300K SBIR), Haplogen Genomics, Immucor, Sciencescape.    [The Scientist, Dec 1, 14]

Edico Genome (San Diego, CA; no SBIR) raised $10 million in Series A financing to commercialize the specialized processor technology it has been developing to slash the time and cost of genome mapping. ...says its technology reduces the computational time required for analyzing a whole human genome from 24 hours to 18 minutes.  [Alex Lash, xconomy.com, Jul 17, 14]

Edico Genome (San Diego, CA; no SBIR) has developed the Dragen Wavefront Processor system that can take data that might require 20 hours to process today and do it in less than 30 minutes, said [CEO] Pieter van Rooyen.  [Mike Freeman, utdandiago.com, Apr 11, 14]

Edison Agrosciences (Durham, NC)

Edison Agrosciences, a biotech company originally from Durham, North Carolina, announced it plans to relocate its headquarters to St. Louis. [with the sweetener of $800K from Missouri Technology Corp]  [Brian Feldt, St. Louis Business Journal, Jan 25, 16]   is developing a sunflower rubber crop that will serve to diversify global rubber production and provide the US with an alternative source for this strategically important commodity.  [company website]

A state-funded biotech startup Edison Agrosciences  (Durham, NC; no SBIR, five employees) developing new ways to turn sunflower into rubber has kicked off a debut $830,000 funder. ... measuring the amount of rubber in plant tissues – the ultimate goal being to create a sunflower plant to be grown for rubber production.  [Lauren K. Ohnesorge Triangle Business Journal, Nov 10, 15]

Editas Medicine (Cambridge, MA)

Editas Medicine up 23% [Jun 30, 21]

Editas Medicine up 30% [Dec 21, 20]

Editas Medicine up 32% [Dec 10, 20] announced it submitted an Investigational New Drug (IND) application with [FDA] for the initiation of a Phase 1/2 clinical trial of EDIT-301, an experimental CRISPR/Cas12a gene editing medicine in development for the treatment of sickle cell disease. [company press release, Dec 9, 20]

Editas Medicine (Cambridge, MA; one SBIR), a leading genome editing company, announced it has regained full global rights to research, develop, manufacture, and commercialize its ocular medicines, including EDIT-101 for the treatment of Leber congenital amaurosis 10, which were previously shared within a strategic research and development alliance with Allergan, which has since been acquired by AbbVie. Editas Medicine and AbbVie have terminated the original agreement and entered into a new agreement. [company press release, Aug 6, 20]

Editas Medicine began a collaboration with Asklepios Biopharmaceutical (RTP, NC; $3.2M SBIR) to explore gene-editing medicines for neurological diseases. No financial terms were disclosed. [Frank Vinluan, xconomy.com, Oct 18, 19]

Editas Medicine up 15% [Mar 1, 19]

The stock price of Editas Medicine sank nearly 20 percent after CEO Katrine Bosley announced without warning she will leave in March. The news comes as Editas prepares to start its first clinical test: An experimental gene-editing therapy for an inherited form of blindness. [Alex Lash, xconomy.com, Jan 25, 19]

Editas Medicine down 20% [Jan 22, 19]

Editas Medicine up 10% [Mar 7, 18]

Editas Medicine up 13% [Jan 29,18]

Editas Medicine up 14% [Jan 22,18]

Editas Medicine down 11% [Jan 8, 18]

Editas Medicine up 12% [Jan 2, 18]

Editas Medecine down 11% [Aug 15,17]

Editas Medicine up 11% [Aug 11,17]

Editas Medicine up 10% [Aug 10, 17]

Homology (Bedford, MA; no SBIR) wrapped up an $83.5 million Series B round ... making the bold claim that its underlying science, technology it calls AMEnDR, is a better version of existing gene editing methods, among them the CRISPR-Cas9 technology that has taken the scientific research world by storm and has led to the formation of three now publicly traded companies, Editas Medicine (Cambridge, MA; no SBIR), Intellia Therapeutics (Cambridge, MA; no SBIR), and CRISPR Therapeutics (Switzerland). [Ben Fidler, xconomy.com, Aug 1, 17]

Editas Medicine up 10% [Jun 7,17]

Stock prices of Editas Medicine,  CRISPR Therapeutics (Switzerland), and Intellia Therapeutics (Cambridge, MA; no SBIR) dropped sharply after the publication of a Nature Methods article that described unintended effects stemming from the use of CRISPR-Cas9 gene-editing technology. But as Xconomy noted two years ago, the possibility of “off-target effects” from use of these tools have long been a concern. [Ben Fidler, xconomy.com, Jun 2, 17]

Editas Medicine down 10% [May 29,17]

Editas Medicine down 10% Mar 17, 17]

 Allergan will pay Editas Medicine (Cambridge, MA; no SBIR) $90 million in cash up front to get an option to license up to five experimental gene editing treatments for eye diseases—including Editas’s lead program, a drug for a rare form of genetic blindness called Leber Congenital Amourosis type 10. ... Editas got a boost in February when founders at the Broad Institute of MIT and Harvard won a patent fight against a group led by the University of California, Berkeley, over ownership of CRISPR-Cas9  [Ben Fidler, xconomy.com, Mar 13, 17]

Editas Medicine down 13% [Feb 22,17]

Editas Medicine up 29% [Feb 15, 17] announced that the U.S. Patent and Trademark Office (USPTO) issued a favorable decision in the CRISPR interference between the University of California, the University of Vienna, Emmanuelle Charpentier and the Broad Institute, Inc. (Broad) regarding certain CRISPR-Cas9 patents the Company exclusively licenses from Broad. [company press release, Feb 15, 17]

Editas Medicine down 10% [Dec 22, 16]

Editas Medicine up 11% [Dec 2, 16]

Editas Medicine down 10% [Oct 25, 16]

Editas Medicine up 11% [Oct 4, 16]

Adverum Biotechnologies (Menlo Park, CA; no SBIR) and Editas Medicine (Cambridge, MA; no SBIR) announced a collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.  This collaboration brings together Adverum’s next-generation adeno-associated viral (AAV) vectors for use with Editas’ leading genome editing technologies to create a series of novel therapies for debilitating eye diseases that have poor therapeutic options. [joint companies press release, Aug 9, 16]

Editas Medicine has licensed CRISPR-Cas9 gene editing work from Massachusetts General Hospital that aims to make more precise cuts in the targeted DNA. Published in January, the technology comes from the lab of Keith Joung, who is an Editas cofounder.  [Ben Fidler, xcomomy.com, Aug 5. 16]

Editas Medicine, a leading genome editing company, announced a three-year agreement with Cystic Fibrosis Foundation Therapeutics, , the nonprofit affiliate of the Cystic Fibrosis Foundation, in which CFFT will pay up to $5 million to Editas Medicine to support the discovery and development of CRISPR/Cas9-based medicines for the treatment of cystic fibrosis (CF). In addition, Editas will access CFFT’s extensive network of CF scientific advisors and clinical researchers.  [company press release, May 16, 16]

Editas Medicine up 13% [May 16, 16]

Intellia Therapeutics (Cambridge, MA; no SBIR)  up 23% [May 6, 16], which owns rights to an important but disputed piece of the CRISPR-Cas9 gene editing technology, .... raised $108 million by IPO.  ....  joins Editas Medicine, Cellectis (France), and Sangamo Biosciences as publicly traded biotechs using gene editing to develop their main products.  [Alex Lash, xconomy.com, May 5, 16]

Editas Medical up 11% [Mar 31, 16]

Editas Medicine up 17% [Mar 11,16]

Editas Medicine down 14% [Mar 10,16]

Editas Medicine down 26% [Mar 9,16]

Editas Medicine up 18% [Mar 3,16]

Editas Medicine up 15% [Feb 26,16]

Editas Medicine up 17% [Feb 22, 16]

Editas Medicine up 10% [Feb 19, 16]

Editas Medicine up 20% [Feb 11, 16]

Editas Medicine  up 14% [Feb 3, 16]  faces a numberof hurdles ... no such therapy has been approved for clinical use in either the U.S. or Europe.  More importantly, Editas doesn’t even know for sure whether it even has the right to use CRISPR. ... already faces competition from two other startups, Intellia Therapeutics (Cambridge, MA; no SBIR) and CRISPR Therapeutics  (Swiss) [which] recently announced a $300-million joint venture with Bayer AG to develop new drugs for a range of illnesses.  [Michael Reilly, technologyreview.com, Feb 3, 16]

Editas Medicine (Cambridge, MA; no SBIR) in the early stage of developing a treatment to correct disease-causing genes in patients, raised $94.4 million in its [IPO]  [Corrie Driebusch, Wall Street Journal, Feb 2, 16]

This biotech company has burned through $75m in the past few years and has not yet started clinical work on a drug candidate. It says it will be many years, “if ever”, before it has something ready to commercialise. If this were not enough, not only is there a thorny patent thicket to manage but the firm must fight and win a case seeking to overturn its own intellectual-property claims on the ground that it was not the first to invent them.  Despite all this, shares in Editas Medicine  (Cambridge, MA; no SBIR), which filed [an IPO], look set to draw great interest from investors. It will be an opportunity to buy into a revolutionary new technology called CRISPR-Cas9, which allows DNA to be cut and edited almost as easily as one might rewrite a document on a computer. Editas, spun out of the work of geneticists at the Broad Institute in Cambridge, Massachusetts, has already raised $163m from private investors and is seeking a further $100m from the markets. Its initial aim is to begin trials by 2017 on a possible treatment for a rare form of blindness.  [The Economist, Jan 9, 16]

Editas Medicine  (Cambridge, MA; no SBIR)  co-founded by Dr Zhang. In early August, Editas raised $120m from a group of investors that includes Bill Gates. This comes on top of $43m the company raised in 2013. [Economist, Aug 22,15] its mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.  [Company website]

UC Berkeley professor Jennifer Doudna won the 2015 Breakthrough Prize in Life Sciences for her research into the CRISPR/Cas9 bacterial defense system, which has become a new method to edit genomes, with potential use in therapeutics. Doudna and her co-winner, French researcher Emmanuelle Charpentier, published a paper in 2012 that is often cited as the key that unlocked the potential of the system. Doudna is a cofounder of Editas Medicine (Cambridge, MA; no SBIR), which is pursuing CRISPR/Cas9-related therapeutics, and of Caribou Biosciences (Berkeley, CA; no SBIR). The prize is part of the series created last year by several Silicon Valley moguls. [Alex Lash, xconomy.com, Nov 13, 14]

[molecular system being used to make genetically engineered laboratory animals more easily than could be done before, with changes in multiple genes] Crispr is moving toward commercial use. Five academic experts recently raised $43 million to start Editas Medicine  (Cambridge, MA)  that aims to treat inherited disease. Other start-ups include Crispr Therapeutics, which is being formed in London, and Caribou Biosciences (Berkeley, CA).  [Andrew Pollack, Nerw York Times, Mar 3, 14]  Serious tech advances can raise serious money.

EEStor

EEStor says that it has taken a big step toward high-volume production of an ultracapacitor-based energy-storage system that, if claims hold true, would far outperform the best lithium-ion batteries on the market. ... But skepticism in the research community is high  [Tyler Hamilton, MIT Tech Review, Aug 5, 08]

EEStor (Cedar Park, TX; no SBIR) has made bold claims about its technology but has so far failed to deliver a working commercial product. However, an agreement announced this month with Lockheed Martin, based in Bethesda, MD, suggests that the company could be making progress--at least enough to convince a major defense contractor that the technology has merit. The agreement gives Lockheed an exclusive international license to use EEStor's power system for military and homeland-security applications  [Tyler Hamilton, MIT Tech Review, Jan 22]

EEStor's secret ingredient is a material sandwiched between thousands of wafer-thin metal sheets, like foil-and-paper gum wrappers stacked on top of each other.  Charged particles stick to the metal sheets and move quickly across EEStor's proprietary material. The result is an ultracapacitor, a batterylike device that stores and releases energy quickly.  "The idea of getting rid of the batteries and putting in capacitors is to get more power back and get it back faster," Hebner said. But he said nothing close to EEStor's claim exists today. [Grant Slater, AP, Sep 4]

Effector Therapeutics (San Diego, CA)

eFFECTOR Therapeutics  (San Diego, CA; no SBIR),  leader in the development of selective translation regulators for the treatment of cancer, today announced that the company has raised $38.6M in Series C financing  ...  to advance a broad Phase 2 development program for eFT508, eFFECTOR’s investigational small molecule MNK1/2 inhibitor, including a combination study in colorectal cancer with avelumab* (BAVENCIO), conducted under a clinical collaboration agreement between eFFECTOR, Pfizer and Merck KGaA  [company press release, Jul 24, 17]

San Diego County companies that raised the largest amount of venture capital in the fourth quarter of 2015
Sapphire Energy ($200K SBIR) $91 million;  Effector Therapeutics: $40 million;  MD Revolution: $22.45 million;  AltheaDX: $20.1 million;  Elcelyx Therapeutics: $20 million;  Amplyx Pharmaceuticals: $20 million;  Astute Medical: $20 million;   Glysens  ($6.8M SBIR): $20 million;  Crinetics Pharmaceuticals  ($200K SBIR): $18 million;   Enlibrium: $15 million   Source: MoneyTree Survey by PricewaterhouseCoopers and the NVCA with data from Thomson Reuters  [xconomy.com]

Effector Therapeutics (San Diego, CA; no SBIR, founded 2012) raised $40 million in venture financing, the biotech said.  .... will support testing of Effector's orally administered cancer drug eFT508 in a Phase 1/2 clinical trial, which looks for evidence of safety and early signs of efficacy. In another trial, the drug will be tested in lymphoma...... derived from the research of UC San Francisco researchers Davide Ruggero and Kevan Shokat. They found that certain proteins involved in disease can be controlled to inhibit the disease while preserving normal cell functions.  [Bradely Fikes, San Diego Union Tribune, Dec 21, 15]

After Switzerland’s Roche paid $230 million in cash to buy Anadys Pharmaceuticals (San Diego, CA; $1.4M SBIR)  in 2011, Anadys CEO Steve Worland ...  began talking prominent academic researchers about hot areas of research and development. ...  led him to UC San Francisco and scientists Kevan Shokat and Davide Ruggero. Together they founded Effector Therapeutics (San Diego, CA;  no SBIR) to develop new small molecule drugs that target translation, a process in the cell for synthesizing proteins. ...   raised $45 million in Series A financing, which should be enough to fund the lead candidate through proof-of-concept studies. [Bruce Bigelow, xconomy.com, May 21, 13]  Successful entrepreneurs attract VC like a magnet.

Egalet (Wayne,PA)

Egalet  (Wayne, PA; no SBIR) a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions,  announced the closing of its previously announced underwritten public offering .. expected to be approximately $30.0 million [company press release, Jul 11, 17]

Egalet (Wayne, PA; no SBIR), specialty pharmaceutical company developing tamper-resistant pain medication, has resolved a patent dispute with Purdue Pharma (Stamford, CT; no SBIR)and Purdue Pharmaceuticals. [John George, Philadelphia Business Journal, May 24, 16]

Egalet (Wayne,PA; no SBIR),  focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the termination of its collaboration with Shionogi Limited around its abuse-deterrent, extended-release hydrocodone product candidate. ... Egalet gains worldwide rights to the Phase 1 product candidate, S-718632.  ... Through the collaboration Egalet received upfront and milestone payments totaling $20 million, as well as an investment of $15 million in Egalet's common stock in connection with Egalet's initial public offering in 2014. All development to date for S-718632 has been funded by Shionogi.  ... In the third quarter Egalet expanded the base of SPRIX prescribers, began commercial promotion of its second product, OXAYDO, and raised $86.3 million through an equity financing   [company press release, Dec 3, 15]

For the third time in the past two weeks, Egalet (Wayne, PA; no SBIR) announced plans to raise cash through a follow-on public stock offering. ...  said it priced a $75 million stock offering.   ... for [R&D] and for sales and marketing efforts of its two approved pain treatments: Oxaydo tablets and Sprix nasal spray.  [John George, Philadelphia Business Journal, Jul 28, 15]

eGenesis (Cambridge,MA)

Biotech startup eGenesis (spun out of Harvard in 2014), which is applying gene editing to animal organs in order to make them suitable for human transplant, has raised $100 million to ramp up work on its kidney program and bring it into human testing. [xconomy.com, Nov 8, 19]

eGenesis (Cambridge, MA; no SBIR) focused on  utilizing  genome  editing technology to make xenotransplantation a routine and lifesaving medical procedure, today announced that it raised a  $38 million Series A financing  ....  Xenotransplantation is the process of grafting or transplanting organs or tissues to humans from other species , and it holds vast potential for filling the tremendous medical need for  healthy organs for transplantation.  [company press release, Mar 16, 17]

Eidos Therapeutics

Eidos Therapeutics (a subsidiary of BridgeBio (Palo Alto, CA. San Francisco, CA; no SBIR, founded 2017)  which develops treatments for a family of rare diseases linked to the buildup of a certain protein in the body, set an initial IPO goal of $115 million. [Frank Vinluan, xconomy.com, May 25, 18]   total funding $64M [crunchbase.com]

Eikos

Grab Your Politician for Plus-Up. Smaller and more transparent earmarks of federal funds for favored domestic projects are returning after a one-year moratorium on the controversial practice. ... a bit less than 1% of total R&D appropriations (3% for DOD) ... The Senate Top 10, are mostly smaller states with senators in key committee chairmanships—Mississippi, New Mexico and Tennessee are at the top ... search AAAS's new database of 2008 earmarks [AAAS Newsletter, Sep 07] But for small business, even 1% is a big honey pot. In the list (August version): Electro Energy  (CT; SBIR), Ocean Power Technologies (OR, SBIR in NJ),  DBS Energy CT, Eikos (MA; $8M+ SBIR), Cellular Bioengineering HI,Cerematec  (UT; SBIR), Ramgen WA, Advanced Radar Technologies WY, Compact Membrane Systems (DE; $20M SBIR), SD Catalyst Group SD.  Your story is that high-tech small business will create jobs, and they don't know whether your claim is valid or just wishful thinking. Like the federal mission agencies who then have to award and supervise the contract, they don't seem much to care.

E-Ink (Cambridge, MA)

Yuan Tai Technologies the Taiwanese video display maker that bought E Ink (Cambridge, MA; no SBIR) last year, announced today that it has changed the international version of its name from Prime View International to E Ink Holdings Inc.  "With this change, Yuan Tai Technologies reaffirms its strong commitment to ePaper, an industry that it has pioneered for over a decade," the company said in a press release E Ink was founded in 1997 by Russell Wilcox and a group of researchers at the MIT Media Lab. The company makes thin black-and-white electronic display screens that simulate the look of ink on paper. The screens are used in most of the world’s electronic book readers, including Amazon.com's popular Kindle devices.  [Boston Globe, Jun 18, 10]

EIS (Vienna, VA)

A massive U.S. Air Force contract has been awarded to a group of five small businesses that will share in the $851 million worth of work, according to Washington Technology ...  sharing the contract:Abacus Technology (Chevy Chase, MD); EIS (Vienna, VA); Odyssey Systems Consulting Group(Wakefield, MA); P3I (Hopkinton, MA); and SpectrumS4 (Burlington, MA). [Dayton Business Journal, Nov 1, 12]  No SBIR to any.

Eko Devices (Berkeley, CA)

Eko Devices (Berkeley, CA; $300K SBIR) granted breakthrough device designation for an electrocardiogram (ECG)-based algorithm that could serve as an easily accessible screening tool for heart failure during routine physical exams. [Meg Bryant, BioWorld.com, Dec 18, 19]

Ekos (Bothell, WA)

EKOS  (Bothell, WA; $4M SBIR) said the FDA cleared its ultrasound device for breaking up pulmonary embolisms, or blood clots in the lungs. The company claims the device, the EkoSonic Endovascular System, is the first FDA-cleared treatment for pulmonary embolism since the drug tPA in 1990. The device helps infuse clot-dissolving drugs into the lung arteries without invasive procedures. EKOS is part of the London-based healthcare firm BTG International [since July 2013]. [Alex Lash, xconomy.com, May 29, 14]

The 18-year-old Ekos (Bothell, WA; $3.6M SBIR) sells an ultrasound device that makes medicine more effective at dissolving blood clots. Since it was introduced in 2005, the EkoSonic Endovascular device has been adopted by more than 490 U.S. hospitals and 100 overseas.  The past couple of years have made Ekos especially attractive. It turned a profit of $2 million on sales. [Robert Celaschi, Puget Sound Business Journal, Jul 12, 13]

London-based health-care company BTG has agreed to buy medical-device maker Ekos (Bothell, WA; $3.5M SBIR, 150 employees)  for $180 million or more, the companies said.... developed an ultrasound-enhanced system for breaking up blood clots, marketed since 2006 and now used in 490 U.S. hospitals and another 100 elsewhere. [Seattle Times, May 24, 13]

Ekos (Bothell, WA; $3.5M SBIR) maker of an ultrasound-based technology for dissolving blood clots, has won approval to market its device against life threatening clots in the lungs among patients in Europe.  [Luke Timmerman, xconomy.com, Jan 17, 11]

EKR Therapeutics (Bedminster, NJ)

Cornerstone Therapeutics (Cary, NC; no SBIR) announced that it is being bought by an Italian pharmaceutical company, ending the Cary drug marketing firm’s five-year run as a publicly traded company. The acquisition values Cornerstone at nearly $300 million  ....  the culmination of Cornerstone’s 2-year-old business strategy of getting specialty drugs to patients by selling directly to hospitals rather than working through doctors. ... Cornerstone was created as a publicly traded company in 2008 when Cornerstone BioPharma (Cary, NC; no SBIR) acquired Critical Therapeutics (Boston, MA; no SBIR) .  ....  Chiesi is a privately held business founded in 1935 in Parma, Italy, with plants or facilities in France, Brazil, England and Rockville, Md. The company employs 3,800 people.  ..... Last year, Chiesi further extended its commitment, agreeing to lend Cornerstone up to $90 million to acquire EKR Therapeutics (Bedminster, NJ; no SBIR) [which] gave Cornerstone the rights to oral hypertension drug Cardene, Cornerstone’s best-selling product today.  [Raleigh News & Observer, Sep 16, 13]

Ekso (Berkeley, CA)

 Ekso Bionics (Richmond, CA; no SBIR) says it will now provide 80 of the rehabilitation suits for the SoldierSocks organization, according to a story on Yahoo finance. ...  announced an expansion of its program to manufacture robotic exoskeleton suits [over the next three years] for the nation's veterans.   [David Mills, San Francisco Business Times, Oct 1, 14]

Mr. Abicca, a 17-year-old from San Diego, is essentially wearing a robot. His bionic suit consists of a pair of mechanical braces wrapped around his legs and electric muscles that do much of the work of walking. It is controlled by a computer on his back and a pair of crutches held in his arms that look like futuristic ski poles....  Ekso (Berkeley, CA; no SBIR) [founded seven years ago by engineers] says it was the first company to introduce a self-contained robotic suit, without any tethers to, say, a power supply . [Brian Chen, New York Times, Sep 11, 12]

Elcelyx Therapeutics (San Diego, CA)

San Diego County companies that raised the largest amount of venture capital in the fourth quarter of 2015
Sapphire Energy ($200K SBIR) $91 million;  Effector Therapeutics: $40 million;  MD Revolution: $22.45 million;  AltheaDX: $20.1 million;  Elcelyx Therapeutics: $20 million;  Amplyx Pharmaceuticals: $20 million;  Astute Medical: $20 million;   Glysens  ($6.8M SBIR): $20 million;  Crinetics Pharmaceuticals  ($200K SBIR): $18 million;   Enlibrium: $15 million   Source: MoneyTree Survey by PricewaterhouseCoopers and the NVCA with data from Thomson Reuters  [xconomy.com]

Elcelyx Therapeutics’ (San Diego, CA; no SBIR, founded 2010) diabetes drug NewMet has passed a mid-stage clinical study, the company said .... said the results support its plan to offer itself for sale to a larger drug company   ..... has raised $43 million in [VC] .....  a “virtual” biotech company. Such companies operate with a handful of core employees doing key tasks and outsource everything else. Virtual biotechs have become common as a more efficient way of advancing products from research into the clinic, without the bureaucracy and overhead of a big company.  [Bradley Fikes, utsandiego.com, Sep 4, 13]

Elcelyx Therapeutics (San Diego, CA; no SBIR) raised $20 million in a Series C venture round led by the GSM Fund, a fund created by Eastbourne Capital portfolio manager Rick Barry solely to invest in Elcelyx.  Alain Baron, who was an entrepreneur in residence at Morgenthaler, founded Elcelyx in 2010 to develop compounds that boost the signal along the appetite-control pathway that tells your brain your gut is full.  [Bruce Bigelow, xconomy.com, Feb 15, 13]

Elcelyx Therapeutics  (San Diego, CA: no SBIR) a stealthy biotech developing new therapeutics for treating diabetes and other metabolic diseases ... has raised just over $6 million from investors in what appears to be the first closing of an early stage round. [signonsandiego,Jan 28, 11]

EectroCell Technologies

ElectroCell Technologies (Colchester, VT; no SBIR), an early graduate of the Vermont Center for Emerging Technologies, has taken in $300,000 of an equity, warrants and options financing, planned for slightly more than $815,000, according to a regulatory filing.  A profile of the company in 2006 noted that ElectroCell develops a technology to treat farm waste with low levels of electricity to reduce odor. The process is also said to improve the environmental impact from wastewater runoff.  [Michelle Lang, Mass High Tech, Mar 2, 11]

ElectroChemical Systems Corp (Ridgewood, NJ)

ElectroChemical Systems Corp (Ridgewood, NJ) started delivery of its advanced FibroMillingTM Etcher equipment which enables the users to produce PWBs, MCMs and other substrates with until now unthinkable advanced designs - all at highly competitive cost. Almost entire electronic manufacturing depends on some form of wet processing involving etching. The FibroMillingTM Etcher has found immediate use in both military and civilian applications. As an inexpensive alternative to traditional equipment it can be directly retrofitted in existing PWB processing lines and provide immediate payback with its superior quality production. CEO Dr. I. V. Kadija, said, " Our first customers are taking advantage of this unique technology and positioning themselves ahead of competition." The commercialization came from a BMDO SBIR with help from the New Jersey Commission on Science and Technology (NJCST).

Electrical Geodesics (Eugene, OR)

The health care arm of European-based technology firm Royal Philips is buying medical device maker Electrical Geodesics (Eugene, OR; $15M SBIR)  for roughly $36.7 million.  [Malia Spencer, Portland Business Journal, Jun 22, 17]

Electric Power Systems (Lombard, IL)

NASA has a nice piece by Mike DiCicco of Goddard Space Flight Center on commercialization from  four NASA SBIR/STTR awardees. Read the stories.. Companies: Serionix (Champaign, IL), Cambrian Innovation (Watertown, MA), Electric Power Systems (Lombard, IL), Zeus (Orangeburg, SC)

Electro Energy (Danbury, CT)

Grab Your Politician for Plus-Up. Smaller and more transparent earmarks of federal funds for favored domestic projects are returning after a one-year moratorium on the controversial practice. ... a bit less than 1% of total R&D appropriations (3% for DOD) ... The Senate Top 10, are mostly smaller states with senators in key committee chairmanships—Mississippi, New Mexico and Tennessee are at the top ... search AAAS's new database of 2008 earmarks [AAAS Newsletter, Sep 07] But for small business, even 1% is a big honey pot. In the list (August version): Electro Energy  (CT; SBIR), Ocean Power Technologies (OR, SBIR in NJ),  DBS Energy CT, Eikos (MA; $8M+ SBIR), Cellular Bioengineering HI, Cerematec  (UT; SBIR), Ramgen WA, Advanced Radar Technologies WY, Compact Membrane Systems (DE; $20M SBIR), SD Catalyst Group SD.  Your story is that high-tech small business will create jobs, and they don't know whether your claim is valid or just wishful thinking. Like the federal mission agencies who then have to award and supervise the contract, they don't seem much to care.

Electro-Energy rose 10% before its afternoon report of 26% higher revenue and gross loss cut 84%. [Nov 20, 06]

Plug-In Hybrid. "If you look at how people typically drive cars, about half of the driving that you use gasoline for you could be using the electricity that comes out of your wall," says Martin Klein, CEO of Electro Energy of Danbury, CT, which developed the battery pack and control system for one of the cars on display in Washington.  100mph and wall plug recharge (although not at instant as pumping gasoline).  Plug-in hybrids have a larger battery pack, which allows them to run on the electric motor much longer -- for 20-25 miles in the case of the Electro Energy car. [MIT Tech Review, May 24  ] [Thanks to Leslie Aitcheson of MDA's Tech App squad] Economics and convenience? Well, think of the benefit from avoiding $3 gasoline and don't ask questions about the total cost per mile for solely gasoline engines and plug-in hybrids. Electricity is NOT free and its cost will vary with the price of gasoline. Electro Energy got early Phase 2 help from BMDO SBIR and then at least four more from other agencies.  Electro Energy says it got a $1M, one year AF contract to keep developing a manufacturing process for its NiMH aircraft battery. The stock is trading at half its six month ago price.  [05]

Electro Energy got a $2M slice of pork to keep developing its bipolar nickel-metal hydride batteries with an Energy Dept earmark (Congressionally directed spending item).  You, too, can go for such pork if your need for money overrides your ideals of lawmaking. Washington lobby houses like Strategic Marketing Innovations do small firms for a living. 

ElectroEnergy suffered a power loss of 15% when it reported soggy earnings. And NVE lost 14% on a dismissive article by Motley Fool  on No Visible Earnings with regard to its supposed licenses that have the market drooling. [Nov 23, 04]

Bipolar lithium for the spooks. Electro Energy (Danbury, CT) got an investment from the CIA's VC (In-Q-Tel) for bipolar design to lithium battery chemistry. CEO Martin Klein made the usual noises We are very pleased with the confidence that In-Q-Tel has shown in our company. EE got its first of only a few SBIRs from SDIO (grandfather of MDA) in 1992, the year of its founding when SDIO believed in funding new companies with entrepreneurial sounding proposals. Since EE joined the CIA portfolio, it has gone back-door public by merger this year and had a $5M private placement. 

Earmark. Electro Energy said it will get $1M from the 2007 DOD budget for continued development of its bipolar wafer-cell Nickel Metal Hydride (NiMH) battery for advanced military aircraft applications.  When an appropriation specifies the vendor of a product or service, it's politics. When Congress specifies a particular recipient of $1M out of a $530,000M budget, its politics.

Electro Energy got an $800K equity investment from In-Q-Tel, CIA's VC arm for advanced rechargeable bipolar lithium ion batteries. [Mass High Tech, Oct 21, 06]

Divided Management.  Electro Energy (Danbury, CT) says it has received funding on two government contracts to continue the manufacturing technology development of its bipolar nickel metal hydride battery for military applications. The company received an additional scope of work and amendment to its contract with the U.S. Air Force that added approximately $1.7M. Electro Energy says it will direct the funds, which will be used over a 12-month period, at the continuation of the manufacturing technology development of bipolar nickel metal hydride batteries for aircraft applications. In addition, under a new contract with the U.S. Army for approximately $848K the company will direct manufacturing technology development at bipolar nickel metal hydride batteries for communication and other applications.  [Mass High Tech, Jun 25] Roughly, Electro Energy has an interesting technology that the military wants. But the US military is not just one entity; it is competing services spending separately appropriated money often for the same technology intended for similar equipment with different colors of paint.  Double management costs and extra costs for the company (reimbursed by the military) to manage two formally different customers. 

Commercial Battery Production Electro Energy (Danbury, CT) plans to enter full commercial production of a battery inspired by the design of fuel cells.... Martin Klein, who co-founded Fuel Cell Energy predecessor Energy Research Corp. in 1970, is ready to take Electro Energy off government contract work and into the commercial sector. To date, EE has subsisted on SBIR from the Department of Energy [and BMDO], and has been working with Ford in Partnership for a New Generation Vehicle. ... EE's patents lie in creating effective seals to prevent fluid leakage which is both a structural and materials problem and in eliminating separate terminals and current collectors, allowing it to make the battery lighter... Founded 10 years ago, Electro Energy was one of the older companies in this month’s Connecticut Venture Fair competition. It took home the Ignite prize for best business plan from a company that has raised $1M or less in venture financing.,, plus $10M in SBIR.[Mass High Tech, May 29]

Electromed (New Prague, MN)

Electromed (New Prague, MN; no SBIR) raised $5.5 million in only the third initial public offering for a Minnesota company since the start of 2008. ...  the manufacturer for the SmartVest System, a Food and Drug Administration-approved device to treat excess lung secretions. ... has reported strong business growth in recent years. [Wendy Lee, Minneapolis Star Tribune, Aug 13, 10]

Electro Optical Sciences  (now MELA Sciences)

Electro-Optical Sciences up 25% [May 26, 10]

Electro-Optical Sciences up 12% [May 10, 10]

Electro-Optical Sciences  down 21% [Mar 25, 10]

Electro-Optical Sciences  down 10% [Jan 22, 10]

Electro-Optical Sciences down 14% [Nov 9, 09]

Electro-Optical Sciences down 12% [Oct 28, 09]M

Electro-Optical Sciences  down 11% [Jul 17, 09]

Electro-Optical Sciences  up 13% [May 1, 09]

Electro-Optical Sciences  up 11% [Mar 26, 09]

Electro-Optical Sciences down 17% [Feb 26, 09]

Electro-Optical Sciences  down 12% [Feb 25, 09]

Electro-Optical Sciences  up 10% [Feb 23, 09]

Electro-Optical Sciences   down 14% [Feb 18, 09]

Electro-Optical Sciences   up 12% [Feb 17, 09]

Electro-Optical Sciences  up 80% [Feb 13, 09] said its experimental device proved effective in detecting melanoma, a type of skin cancer, sending its shares soaring   [Reuters]

Electro-Optical Sciences   up 28% [Feb 6, 09]

Electro-Optical Sciences down 26% [Feb 5, 09]

Electro-Optical Sciences down 13% [Feb 4, 09]

Electro-Optical Sciences  up 11% [Jan 28, 09]

Electro-Optical Sciences up 25% [Dec 30, 08]

Electric-Optical Sciences down 17% [Dec 15, 08]

Electro-Optical Sciences up 13% [Dec 8, 08]

Electro-Optical Sciences up 13% [Nov 26, 08]

Electric-Optic Science up 19% [Oct 31, 08]

ElectroOptical Science down 14% [Oct 24, 08]

Electro Optical Science down 11% [Oct 23, 08]

Electro-Optical Sciences up 10% [May 27, 08]

Electro-Optical Sciences up 13% [May 16, 08]

Electro-Optical Sciences up 18%  [May 2, 08]

Electro-Optical Sciences up 27% [Mar 24, 08]

Electro-Optical Sciences rose 14% after announcing the initiation of the pivotal clinical trial for MelaFind®, the company's non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma  [Feb 21, 07]

Electro-Optical Science up 11%. [Nov 15, 06]

Electro-Optical Sciences, a medical-device company, traded at $7.7 after its IPO at $5.  EOS got part of its start with three Phase 2 SBIRs in the mid 1990s. The $5 was a big come-down from its summer dream of $10-12, says the Wall Street Journal (Nov 1).

Electro Scientific

Electro Scientific Industries down 10% [Jan 29, 15]

Electro Scientific Industries up 13% [Aug 1, 14]

Zygo (one Phase 1 SBIR) is among the more successful Connecticut-bred tech firms, with 375 local employees and a solid market niche. Its merger [with Electro Scientific (no SBIR)] — which is being contested in court by a shareholder group — would leave Zygo under the control of another company. But that is the best plan for nurturing the business, Zygo officials said. ... The deal is typical of a market where tech companies are searching for growth and capital, said Matthew Nemerson, president and CEO of the Connecticut Technology Council. [Kenneth St Onge, Hartford Courant, Dec 19, 08]

Electrozyme (San Diego, CA

Biosensor startup Biolinq (formerly Electrozyme, San Diego, CA; $2.2M SBIR, founded 2012) said it has raised $4.75 million from new investors, including the New York-based Juvenile Diabetes Research Foundation, following the results of a clinical study of its experimental biomarker monitoring device. .... seeking to commercialize a nickel-sized patch that’s designed to gauge blood-glucose level and take other measurements when the device is applied to the skin.  [Sarah de Crescenzo, xconomy.com, Mar 28, 19] prior funding $10M [crunchbase.com]

Elementary Robotics

Elementary Robotics (Los Angeles, CA; no SBIR, founded 2017) announced a $12.7M Series A funding round .... has built a hardware and software platform for applying machine learning and computer vision for intelligent automation of quality and traceability workflows in manufacturing and logistics. .... is working with a number of world class manufacturing and logistics companies [company press release, Jul 8, 20]

Elementary Robotics announced a $3.6 million seed raise ... With a team of experts culled from the Pasadena-based NASA Jet Propulsion Lab, Caltech and the ArtCenter College of Design, Elementary Robotics puts its talent to work building “robust, intelligent robot assistants that are affordable and human,” according to its website.  [Samson Amore, LA Business Journal, Dec 19, 18]  in stealth mode [company website]

Elemetric Instruments (Los Alamos, NM)

Los Alamos National Laboratory has approved $250,000 in new funding for four companies from its Venture Acceleration Fund [which] provides investments of up to $100,000 to regional entrepreneurs, companies, investors or strategic partners who use LANL technology or expertise to create or grow regional businesses. Award recipients are chosen based on potential for regional impact, team composition, technical feasibility, market opportunity, and the availability of matching funds or in-kind contributions. Retriever Technology (Santa Fe, NM; no SBIR) will receive $25,000 to upgrade a low-light imaging camera for advanced digital imaging into a more user-friendly and functional form for customer demonstration and evaluation.  Elemetric Instruments (Los Alamos, NM; no SBIR) will get $100,000 to further develop a prototype of an instrument that immediately detects elements in liquids and gases with continuous online, real-time processing. The device, called an element presence detector, is based on LANL technology with potential markets among food and pharmaceutical makers.  STAR Cryoelectronics (Santa Fe, NM; $2M SBIR) will get $75,000 to accelerate development of a high-resolution alpha particle spectrometer to be used in nuclear forensics and nuclear nonproliferation work.  Veezyon (somewhere, NM; no SBIR) will receive $50,000 to improve the technical capabilities of its Veezyon.com Web site — a knowledge-based online video site focusing on shared interest user collaboration.  Since the venture fund was launched in fall 2006, LANL has awarded about $600,000 to six companies, not including the new grants, [New Mexico Business Weekly, Jan 7, 09]

ElevateBio

ElevateBio (Cambridge, MA) biotechnology holding company, announced it has established and launched HighPassBio, a company dedicated to advancing novel targeted T cell immunotherapies. [Nick Paul Taylor, Fierce Biotech, Oct 1, 2019]

ElevateBio unveiled $150 million in Series A funding to back its plans to invest in cell and gene therapy startups, and build a shared facility in Waltham, MA, that will manufacture their experimental treatments. [Frank Vinluan, xconomy.com, May 17, 19]

Elevation Pharmaceuticals (San Diego, CA)

the Marlborough [MA]-based subsidiary of a big Japanese drug company, said it has agreed to buy Elevation Pharmaceuticals (San Diego, CA; no SBIR, founded 2008)  specializing in the development of aerosol therapies for patients with respiratory diseases. Sunovion said it will make an upfront payment of $100 million to the shareholders of California-based Elevation on the closing of the acquisition. The sales agreement also calls for more than $300 million in additional milestone payments if certain conditions are met. [Chris Reidy, Boston Globe, Aug 30]

Elevation Pharmaceuticals (San Diego, CA; no SBIR, founded 2008) startup developing aerosol-based treatments for respiratory diseases, said it has raised a tranched $30 million in Series A venture funding. It’s a sizable round for the [San Diego] life sciences community, but other recent fundings have come close. Last month, VentiRx(no SBIR) raised $25 million, Pfenex (no SBIR) got $24 million, and Zogenix (no SBIR)  got $20 million.  [Bruce Bigelow, signonsandiego.com, Mar 8, 10]

Elevation Pharmaceuticals  (San Diego, CA; no SBIR) a biotech startup developing aerosol-based treatments for respiratory diseases, said today it has raised a tranched $30 million in Series A venture funding [Bruce Bigelow, San Diego, Union Tribune, Feb 24, 10]

Elevian ((Allston, MA)

Early-stage biotech Elevian (Allston, MA; no SBIR) raised $15 million as it looks to target multiple age-related diseases. The company said the small raise would help its preclinical work toward the clinic to treat stroke and other age-related diseases. [Fierce Biotech, Nov 23, 20]

Elixir Biopharm

Bioheartand ElixirBiopharm going public this week.  Neither used SBIR. [Jan 08]

Elixir Pharmaceuticals (Cambridge, MA)

Elixir Pharmaceuticals is calling off its IPO.  The 9 year-old biotech says it has raised a total of $87 million in three rounds of VC. [Mass High Tech, May 12, 08]

Elixir Pharmaceuticals that was expected to go public this week, has postponed its initial public
offering,. [Boston Globe, Jan 18]

Elixir Pharmaceuticals  (Cambridge MA; no SBIR)  plans fan IPO for $86 M. With 30 employees it most recently raised $10M VC from Swiss drug giant Novartis AG atop an already $100M from US VCs. [Mass High Tech, Sep 24, 07]

Ellipse Technologies (Aliso Viejo, CA)

Medical device maker NuVasive (no SBIR) paid $380 million in cash upfront to buy Ellipse Technologies  (Aliso Viejo, CA; no SBIR) which could get an additional $30 million in milestone payments. Ellipse has developed implantable rods that can be lengthened magnetically to help correct spinal and complex skeletal deformities. The technology would help extend NuVasive’s own line of spinal surgical tools. [Alex Lash, xconomy.com, Jan 8, 16]

Elon

Elon  down 10% [Feb 10, 12]

Elon down 19% [Nov 4, 11]

Elon up 10% [Oct 4, 11]

Elon up 15% [May 6, 11]

Elstar Therapeutics (Cambridge, MA)

Elstar Therapeutics (Cambridge, MA; no SBIR, founded 2015) fulfilling the promise of precision cancer immunotherapy through a powerful new approach to generating multi-functional therapies, announced the closing of a $39M Series A financing round [to] expand its growing pipeline and progress several early stage molecules towards the clinic immunotherapies.  [company press release, Jan 3, 18]